Document and Entity Information
Document and Entity Information - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Feb. 04, 2022 | Jun. 30, 2021 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Period End Date | Dec. 31, 2021 | ||
Document Fiscal Year Focus | 2021 | ||
Document Fiscal Period Focus | FY | ||
Trading Symbol | ALVR | ||
Entity Registrant Name | ALLOVIR, INC. | ||
Entity Central Index Key | 0001754068 | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Current Fiscal Year End Date | --12-31 | ||
Document Annual Report | true | ||
Document Transition Report | false | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | true | ||
Entity Ex Transition Period | false | ||
ICFR Auditor Attestation Flag | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 598.9 | ||
Entity Common Stock, Shares Outstanding | 65,345,501 | ||
Security12b Title | Common Stock, par value $0.0001 per share | ||
Security Exchange Name | NASDAQ | ||
Entity File Number | 001-39409 | ||
Entity Incorporation State Country Code | DE | ||
Entity Tax Identification Number | 83-1971007 | ||
Entity Address Address Line1 | 1100 Winter Street | ||
Entity Address City Or Town | Waltham | ||
Entity Address State Or Province | MA | ||
Entity Address Postal Zip Code | 02451 | ||
City Area Code | 617 | ||
Local Phone Number | 433-2605 | ||
Documents Incorporated by Reference | Portions of the Proxy Statement for the registrant’s 2022 Annual Meeting of Stockholders, or the Proxy Statement, which the Registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the Registrant’s fiscal year end of December 31, 2021 , are incorporated by reference into Part III of this Annual Report on Form 10-K. | ||
Auditor Firm ID | 34 | ||
Auditor Name | Deloitte & Touche LLP | ||
Auditor Location | Boston, MA, USA |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Current assets: | ||
Cash and cash equivalents | $ 201,661 | $ 122,661 |
Short-term investments | 46,459 | 233,663 |
Accrued interest | 50 | 450 |
Prepaid expenses and other current assets | 5,178 | 4,543 |
Total current assets | 253,348 | 361,317 |
Restricted Cash | 852 | |
Other Assets | 1,102 | |
Property and equipment, net | 1,549 | 812 |
Operating lease right-of-use assets | 29,743 | 8,692 |
Total assets | 286,594 | 370,821 |
Current liabilities: | ||
Accounts payable | 8,361 | 963 |
Accrued expenses | 20,152 | 7,530 |
Income tax payable | 1,007 | |
Operating lease liability, current | 6,591 | 3,229 |
Amount due to related party | 1,742 | 572 |
Total current liabilities | 37,853 | 12,294 |
Operating lease liability, long term | 23,475 | 5,463 |
Total liabilities | 61,328 | 17,757 |
Stockholders’ equity (deficit): | ||
Preferred stock, $0.0001 par value: 10,000,000 and 0 shares authorized at December 31, 2020 and 2019, respectively; 0 shares issued and outstanding at December 31, 2020 and 2019, respectively; | ||
Common stock, $0.0001 par value: 150,000,000 and 90,000,000 shares authorized at December 31, 2020 and 2019, respectively; 65,106,873 and 6,502,929 shares issued at December 31, 2020 and 2019, respectively; and 61,931,255 and 2,099,740 shares outstanding at December 31, 2020 and 2019, respectively | 7 | 7 |
Additional paid-in capital | 522,479 | 478,272 |
Accumulated other comprehensive (loss) income | (155) | (112) |
Accumulated deficit | (297,065) | (125,103) |
Total stockholders’ equity (deficit) | 225,266 | 353,064 |
Total liabilities, convertible preferred stock and stockholders’ equity (deficit) | $ 286,594 | $ 370,821 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares | Dec. 31, 2021 | Dec. 31, 2020 |
Preferred stock, par or stated value per share | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized | 10,000,000 | 10,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 150,000,000 | 150,000,000 |
Common stock, shares issued | 65,170,332 | 65,106,873 |
Common stock, shares outstanding | 63,565,886 | 61,931,255 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Operating expenses: | ||
Research and development | $ 120,735 | $ 49,663 |
General and administrative | 49,083 | 21,646 |
Total operating expenses | 169,818 | 71,309 |
Loss from operations | (169,818) | (71,309) |
Total other income (loss), net: | ||
Interest income | 1,315 | 1,330 |
Other (loss) income, net | (2,452) | 195 |
Loss before income taxes | (170,955) | (69,784) |
Income tax expense | 1,007 | |
Net loss | $ (171,962) | $ (69,784) |
Net loss per share – basic and diluted | $ (2.74) | $ (2.59) |
Weighted-average common shares outstanding – basic and diluted | 62,782,126 | 26,897,390 |
Comprehensive loss: | ||
Net loss | $ (171,962) | $ (69,784) |
Other comprehensive income (loss), net of tax: | ||
Unrealized gain (loss) on available-for-sale securities | 1 | (90) |
Foreign currency translation adjustment | (44) | (90) |
Total other comprehensive loss | (43) | (180) |
Comprehensive loss | $ (172,005) | $ (69,964) |
CONSOLIDATED STATEMENTS OF CONV
CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands | Total | Common Stock | Additional Paid-In Capital | Accumulated Other Comprehensive Income | Accumulated Deficit | Series B Preferred Stock | Series A Preferred Stock |
Balance at Dec. 31, 2019 | $ (51,503) | $ 3,748 | $ 68 | $ (55,319) | |||
Temporary equity, Balance, Shares at Dec. 31, 2019 | 14,877,697 | 44,520,653 | |||||
Temporary equity, Balance at Dec. 31, 2019 | $ 120,923 | $ 52,204 | |||||
Balance, Shares at Dec. 31, 2019 | 2,099,740 | ||||||
Initial public offering, net of underwriting discounts, commissions and offering costs | 291,975 | $ 2 | 291,973 | ||||
Initial public offering, net of underwriting discounts, commissions and offering costs, Shares | 18,687,500 | ||||||
Temporary equity conversion of convertible preferred stock into common stock upon initial public offering, Shares | (14,877,697) | (44,520,653) | |||||
Temporary equity conversion of convertible preferred stock into common stock upon initial public offering | $ (120,923) | $ (52,204) | |||||
Conversion of convertible preferred stock into common stock upon initial public offering | 173,127 | $ 5 | 173,122 | ||||
Conversion of convertible preferred stock into common stock upon initial public offering, Shares | 39,859,139 | ||||||
Stock-based compensation | 9,429 | 9,429 | |||||
Issuance of common stock, upon vesting of restricted stock, Shares | 1,284,876 | ||||||
Unrealized gain (loss) on available-for-sale securities | (90) | (90) | |||||
Foreign currency translation adjustment | (90) | (90) | |||||
Net loss | (69,784) | (69,784) | |||||
Balance at Dec. 31, 2020 | 353,064 | $ 7 | 478,272 | (112) | (125,103) | ||
Balance, Shares at Dec. 31, 2020 | 61,931,255 | ||||||
Stock-based compensation | 43,975 | 43,975 | |||||
Issuance of common stock, upon vesting of restricted stock, Shares | 1,609,479 | ||||||
Issuance of common stock, upon exercise of common stock | $ 232 | 232 | |||||
Issuance of common stock, upon exercise of common stock, Shares | 25,152 | 25,152 | |||||
Unrealized gain (loss) on available-for-sale securities | $ 1 | 1 | |||||
Foreign currency translation adjustment | (44) | (44) | |||||
Net loss | (171,962) | (171,962) | |||||
Balance at Dec. 31, 2021 | $ 225,266 | $ 7 | $ 522,479 | $ (155) | $ (297,065) | ||
Balance, Shares at Dec. 31, 2021 | 63,565,886 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Cash flows from operating activities | ||
Net loss | $ (171,962) | $ (69,784) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 189 | 73 |
Non-cash lease expense | 928 | |
Amortization and accretion of discounts on short-term investments | 1,197 | 502 |
Stock compensation expense | 43,975 | 9,429 |
Changes in operating assets and liabilities: | ||
Unbilled grant receivables | 298 | |
Accrued interest | 400 | (188) |
Prepaid expenses and other current assets | (1,241) | (3,867) |
Other assets | (1,102) | |
Income tax payable | 1,007 | |
Accounts payable, accrued expenses and amount due to related party | 20,290 | 2,726 |
Net cash used in operating activities | (106,319) | (60,811) |
Cash flows from investing activities | ||
Purchase of property and equipment | (26) | (235) |
Purchase of short-term investments | (76,591) | (300,262) |
Maturities of short-term investments | 262,600 | 131,000 |
Net cash provided by (used in) investing activities | 185,983 | (169,497) |
Cash flows from financing activities | ||
Payment of initial public offering costs | (3,474) | |
Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts of $22,238 | 295,449 | |
Proceeds from exercise of stock options | 232 | |
Net cash provided by financing activities | 232 | 291,975 |
Effect of exchange rate changes on cash, cash equivalents, and restricted cash | (44) | (90) |
Net increase in cash, cash equivalents, and restricted cash | 79,852 | 61,577 |
Cash, cash equivalents, and restricted cash at beginning of period | 122,661 | 61,084 |
Cash, cash equivalents, and restricted cash at end of period | 202,513 | 122,661 |
Non-cash investing and financing activities | ||
Unrealized gain (loss) on available-for-sale securities | 1 | (90) |
Right-of-use assets obtained in exchange for operating lease liability | 26,386 | |
Purchase of property and equipment included in AP and accrued expenses | 899 | 300 |
Conversion of preferred stock to common stock upon initial public offering | 173,127 | |
Cash and cash equivalents | 201,661 | 122,661 |
Restricted Cash | 852 | |
Total cash, cash equivalents, and restricted cash | $ 202,513 | $ 122,661 |
CONSOLIDATED STATEMENTS OF CA_2
CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) $ in Thousands | 12 Months Ended |
Dec. 31, 2020USD ($) | |
Statement of Cash Flows [Abstract] | |
Underwriting discounts, amount | $ 22,238 |
Nature of the Business
Nature of the Business | 12 Months Ended |
Dec. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Nature of the Business | 1. Nature of the Business AlloVir, Inc. (“AlloVir” or “the Company”, formerly known as ViraCyte, Inc.) is a leading late clinical-stage cell therapy company developing highly innovative allogeneic T cell therapies to treat and prevent devastating viral diseases. The Company’s innovative and proprietary virus-specific T cell, or VST, therapy platform allows AlloVir to generate off-the-shelf VSTs designed to restore immunity in patients with T-cell deficiencies who are at risk from the life-threatening consequences of viral diseases. There is an urgent medical need for therapies to treat a large number of patients suffering from viral diseases who currently have limited or no treatment options. The Company is developing four innovative, allogeneic, off-the-shelf VST therapy candidates targeting 12 different devastating viruses. The most advanced is posoleucel (previously referred to as Viralym-M or ALVR105), for which the Company has an ongoing pivotal trial for the treatment of virus-associated hemorrhagic cystitis, or HC, and for the treatment of adenovirus, or AdV, infections and ongoing proof-of-concept, or POC, clinical trials for multi-virus prevention in HCT and for BKV treatment in kidney transplant. The Company's lead product candidate, posoleucel, is a multi-VST cell therapy that targets six viruses: AdV, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus. Posoleucel has the potential to fundamentally transform the treatment landscape for transplant patients by substantially reducing or preventing disease morbidity and mortality, thereby dramatically improving patient outcomes. To fully explore the clinical benefit of posoleucel, the Company plans three Phase 3 pivotal and one Phase 2 POC trial in 2022 for the treatment and prevention of life-threatening viral diseases in pediatric and/or adult allogeneic HCT patients, each representing a potential meaningful commercial opportunity. Two of the Phase 3 clinical trials – one in virus-associated HC and one in AdV infection in HCT patients – and a POC trial in BKV are ongoing. A third Phase 3 trial in multi-virus prevention in high-risk allogeneic HCT patients is expected to initiate in the first half of 2022. The Company’s pipeline includes additional investigational VST therapies that may benefit high-risk individuals. ALVR106 is the Company’s second off-the-shelf, multi-VST product candidate targeting devastating respiratory diseases caused by human metapneumovirus, or hMPV, influenza, parainfluenza virus, or PIV and respiratory syncytial virus, or RSV. A Phase 1/2 POC clinical study of ALVR106 opened for enrollment at the end of 2021. ALVR109 is an allogeneic, off-the-shelf, single virus-targeted cell therapy designed to target SARS-CoV-2, the virus that causes the severe and life-threatening viral disease, COVID-19. Data from the POC clinical trial of ALVR109 were reported in 2021, and the Company continues to make ALVR109 available to physicians in response to appropriate compassionate use requests. In the preclinical space, the Company is advancing ALVR107 designed to target hepatitis B, or HBV, infected cells and with the aim of curing chronic HBV infection. Preclinical and IND-enabling studies of ALVR107 to treat and cure HBV will be completed in 2022 to support advancement into a POC study. The Company was formed on August 16, 2013 as a Delaware limited liability company (“LLC”) under the name AdCyte LLC and on July 29, 2014 the Company changed its name to ViraCyte LLC. On September 17, 2018, the Company converted from a Delaware LLC to a Delaware corporation (“LLC Conversion”) and changed its name to ViraCyte, Inc. On May 22, 2019, the Company changed its name to AlloVir, Inc. The Company has principal offices in Waltham, Massachusetts, Houston, Texas and Cambridge, Massachusetts. On August 8, 2019, AlloVir formed AlloVir International Designated Activity Company (“AlloVir International”), a wholly-owned subsidiary established in Ireland. On October 9, 2019, AlloVir Securities Corporation was incorporated as a Massachusetts Security Corporation, a wholly-owned subsidiary of AlloVir. On November 10, 2019, AlloVir International formed AlloVir Italia S.R.L. (“AlloVir Italia”), a wholly-owned subsidiary in Italy. On August 3, 2020, the Company completed an initial public offering (“IPO”) in which the Company issued and sold 18,687,500 shares of its common stock, at a public offering price of $ 17.00 per share, resulting in gross proceeds of $ 317.7 million. The Company received $ 292.0 million in net proceeds after deducting underwriting discounts and commissions and offering costs. Upon the closing of the IPO, all of the then-outstanding shares of convertible preferred stock automatically converted into 39,859,139 shares of common stock at the applicable conversion ratio then in effect. Subsequent to the closing of the IPO, there were no shares of convertible preferred stock outstanding. On July 20, 2021 AlloVir Inc formed AlloVir U.S., Inc. (“AlloVir U.S.”), a wholly-owned subsidiary of AlloVir. ElevateBio LLC On September 17, 2018, the Company executed a Series A2 Preferred Stock Purchase Agreement (“Series A2 Agreement”) with ElevateBio, LLC, a Delaware LLC (“ElevateBio”) concurrent with the LLC Conversion. ElevateBio was formed on November 29, 2017 and is headquartered in Cambridge, Massachusetts with a focus on the development of a portfolio of novel cell therapy programs acquired through business development activities with biotechnology companies. ElevateBio is structured as a holding company, comprised of asset-specific subsidiaries focused on the development of pipeline assets, as well as a manufacturing subsidiary with the expertise to provide drug development and manufacturing services. As a result of the purchase of the Company’s Series A2 Preferred Stock, ElevateBio acquired an ownership interest in the Company. The Chief Executive Officer, Chief Financial Officer, and other executives of ElevateBio have previously or currently serve in similar management roles with AlloVir. In May 2021, Diana M. Brainard M.D., succeeded David Hallal, ElevateBio's Chief Executive Officer, as the Company’s Chief Executive Officer and principal executive officer. Going Concern In accordance with Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40) , the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the consolidated financial statements are issued. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Through December 31, 2021, the Company has funded its operations primarily with proceeds received from the sale of common stock, research grants, and from the sale of preferred stock. The Company has incurred recurring losses since its inception, including net losses attributable to common stockholders of $ 172.0 million for the year ended December 31, 2021 and $ 69.8 million for the year ended December 31, 2020. In addition, at December 31, 2021, the Company had an accumulated deficit of $ 297.1 million. The Company expects to continue to generate operating losses for the foreseeable future. The Company believes that its $ 201.7 million of cash and cash equivalents and $ 46.5 million of short-term investments held at December 31, 2021, are sufficient to fund planned operations for at least twelve months from the date that these consolidated financial statements are available to be issued. COVID-19 Considerations The development of product candidates could be disrupted and materially adversely affected in the future by a pandemic, epidemic or outbreak of an infectious disease, such as the recent COVID-19 pandemic. The spread of COVID-19 has impacted the global economy and has impacted the Company’s operations, including the interruption of preclinical and clinical trial activities and potential interruption to the Company’s supply chain. For example, the COVID-19 pandemic has delayed clinical trials. If the disruption due to the COVID-19 pandemic continues, planned pivotal clinical trials also could be delayed due to government orders and site policies on account of the pandemic, and some patients may be unwilling or unable to travel to study sites, enroll in trials or be unable to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services, which would delay the Company’s ability to conduct preclinical studies and clinical trials or release clinical trial results and could delay the Company’s ability to obtain regulatory approval and commercialize product candidates. Furthermore, COVID-19 could affect the Company’s employees or the employees of research sites and service providers on whom the Company relies on as well as those of companies with which the Company does business, including suppliers and contract manufacturing organizations or CMOs, thereby disrupting business operations. Quarantines and travel restrictions imposed by governments in the jurisdictions in which the Company and the companies with which it does business operate could materially impact the ability of employees to access preclinical and clinical sites, laboratories, manufacturing sites and offices. For the health and safety of our employees, the Company has implemented work-at-home policies and we have generally restricted on site staff to only those employees who are fully vaccinated or essential to the development and research of product candidates; accordingly, the Company may experience limitations in employee resources. The outbreak and any other preventative or protective actions that the Company, its suppliers or other third parties with which it has business relationships, or governments may take in respect of the COVID-19 pandemic, could disrupt, delay or otherwise adversely impact the business. The Company is still assessing business plans and the impact the COVID-19 pandemic may have on its ability to advance the testing, development and manufacturing of drug candidates, including as a result of adverse impacts on the research sites, service providers, vendors, or suppliers on whom the Company relies on, or to raise financing to support the development of our drug candidates. No assurances can be given that this analysis will enable the Company to avoid part or all of any impact from the spread of COVID-19 or its consequences, including downturns in business sentiment generally or this sector in particular. The Company cannot presently predict the scope and severity of any potential business shutdowns or disruptions, but if the Company or any of the third parties on whom it relies on or with whom it conducts business, were to experience shutdowns or other business disruptions, the Company’s ability to conduct business in the manner and on the timelines presently planned could be materially and adversely impacted. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | 2. Summary of Significant Accounting Policies Basis of Presentation and Consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The consolidated financial statements include the Company’s accounts and those of its wholly-owned subsidiaries. All intercompany accounts, transactions and balances have been eliminated in consolidation. Segment Information Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has one operating segment. The Company’s singular focus is the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purpose of allocating resources. All of the Company’s long-lived assets are held in the United States. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates. Cash and Cash Equivalents Cash and cash equivalents are short-term, highly liquid investments with original maturities of three months or less at the date of purchase. Investments qualifying as cash equivalents primarily consist of money market funds, corporate bonds and commercial paper. Short-Term Investments Short-term investments consist of U.S. treasury securities, corporate bonds and commercial paper classified as available-for-sale that have maturities of less than one year . Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive income (loss). The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization or accretion is included in "other income (loss), net". The cost of securities sold is based on the specific identification method. Interest on debt securities classified as available-for-sale are included in interest income. To determine whether an other-than-temporary impairment exists, the Company considers whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability of the cost of the investment outweighs evidence to the contrary. There were no individual securities with impairments at December 31, 2021 and 2020 . Restricted Cash Cash accounts with any type of restriction are classified as restricted cash. The Company has restricted cash deposits with a bank, which serve as collateral for a letter of credit issued to the landlord of the Company’s leased Waltham facility for a security deposit. The Company classified this amount as non-current restricted cash in the accompanying condensed consolidated balance sheet at December 31, 2021 . There was no restricted cash balance at December 31, 2020 . Property and Equipment, Net The Company records property and equipment at cost and recognizes depreciation using the straight-line method over the estimated useful lives of the respective assets , as follows: Asset category Estimated useful life Computer equipment 3 years Laboratory equipment 5 years The Company periodically evaluates whether events and circumstances have occurred that may warrant revision of the estimated useful life of property and equipment. Expenditures for repairs and maintenance of assets are expensed as incurred. Upon retirement or sale, the cost of assets disposed and the corresponding accumulated depreciation are removed from the related accounts and any resulting gain or loss is reflected in the results of operations. Construction in progress is not depreciated until it is placed in service. Property and equipment to be disposed of are carried at fair value less costs to sell. Impairment of Long-Lived Assets The Company accounts for long-lived assets in accordance with ASC Topic 360, Property, Plant, and Equipment (“ASC 360”). ASC 360 requires companies to: (i) recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and (ii) measure an impairment loss as the difference between the carrying amount and the fair value of the asset. The Company tests long-lived assets to be held and used, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of assets or asset groups may not be fully recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. The Company has no t recognized any impairment losses during the years ended December 31, 2021 and 2020 . Fair Value Measurements ASC Topic 820, Fair Value Measurement (“ASC 820”), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes among the following: • Level 1 – Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. • Level 2 – Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. • Level 3 – Valuations based on inputs that are unobservable and significant to the overall fair value measurement. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company’s financial instruments include cash equivalents, short-term investments, accounts payable, amount due to related party and accrued expenses. Certain of the Company’s financial assets, including cash equivalents and short-term investments, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models and observable market inputs to determine value. Other financial instruments, including accounts payable, amount due to related party and accrued expenses, are carried at cost, which approximate fair value due to the short duration and term to maturity. Deferred Offering Costs The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are presented in the consolidated balance sheets as a direct reduction from the carrying amount of the respective equity instrument issued. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss. Upon closing the IPO in August 2020, deferred offering costs were derecognized and recorded against the IPO proceeds as a debit to additional paid-in capital. At December 31, 2021 and 2020 , the Company had no deferred offering costs. Cloud Computing Arrangements The Company capitalizes certain implementation costs for internal-use software incurred in a cloud computing agreement that is a service contract. Eligible costs associated with cloud computing arrangements, such as the implementation costs incurred to develop or obtain software business applications used in the normal course of business, are capitalized in accordance with ASC 350. Capitalization ceases at the point the software is substantially complete and ready for its intended use, and after all substantial testing is completed. Amortization is recorded on a straight-line basis over the expected useful life of three years of the internal-use software cost in the same line item in the statement of operations and comprehensive loss as the expense for fees for the associated cloud computing arrangement. Amortization expense associated with the Company's cloud computing arrangements has been recognized in the amount of $ 0.1 million and $ 0 during the years ended December 31, 2021 and 2020 . Other Income (Loss), Net The Company records interest expense, investment amortization and accretion and other government grants, not considered customers under ASC 606, in “other income (loss), net” over the same period in which the qualifying costs are incurred. Proceeds received from other government grants prior to the costs being incurred or the conditions of the award being met are recognized as deferred grant income until the services are performed and the conditions of the grant are met. To the extent that qualifying costs have been incurred prior to receipt of funds, the Company records an unbilled grant receivable upon recognition of those expenses. Research and Development Costs Research and development costs are charged to expense as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, stock-based compensation, facilities, research-related overhead, clinical trial costs, contracted services, research-related manufacturing, license fees and other external costs. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the services have been performed or when the goods have been received. Accrued Research and Development Expenses The Company has entered into various research and development contracts. The payments under these contracts are recorded as research and development expenses as incurred. The Company records accrued liabilities for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Judgements and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. The Company’s historical accrual estimates have not been materially different from the actual costs. Research and Development Grants Grants are recognized as a rec eivable at their fair value when there is reasonable assurance that the grant will be received and the Company will comply with all the attached conditions. Grants receivable are recognized on a systematic basis as income over the periods necessary to match them with the related costs which they are intended to compensate. Grants that have been earned, other than those grants that fall under ASC 606, where the Company determined that the grantor is a customer, are presented in the consolidated statements of operations and comprehensive loss as “other income (loss), net”. Stock-Based Compensation Expense The Company grants restricted stock and stock options to employees, consultants and directors. The Company recognizes stock-based compensation cost for awards with performance conditions if and when it concludes that it is probable that the performance conditions will be achieved. For awards with only a service condition, the Company expenses stock-based compensation on a straight-line basis over the requisite employee service period or for grants issued with performance conditions, on a graded-vesting basis over the requisite employee service period. Awards for employees and non-employees are accounted for similarly. The Company records stock-based compensation expense associated with grants of restricted stock and stock options in the consolidated statements of operations and comprehensive loss based on their estimated fair value at the date of the grant. The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the grantee’s payroll costs are classified or in which the grantee’s service payments are classified. Forfeitures are accounted for as they occur. The fair value of each stock option grant is estimated on the date of grant using the Black‑Scholes option pricing model. As there was no public market for the Company’s common stock prior to the initial public offering of its common stock in August 2020, the estimated fair value of common stock was determined by the Company’s board of directors as of the date of each option grant, with input from management, considering third-party valuations of its common stock, as well as the Company’s board of directors’ assessment of additional objective and subjective factors that it believed were relevant, and which may have changed from the date of the most recent third-party valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants’ Accounting and Valuation Guide, Valuation of Privately Held Company Equity Securities Issued as Compensation. Following the closing of the initial public offering, the fair value of the Company’s common stock is determined based on the quoted market price of common stock. The Company also lacks company‑specific historical and implied volatility information for its stock. The Company estimates its expected stock price volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company’s stock options has been determined utilizing the “simplified” method. The “simplified” method estimates the expected term of stock options as the mid‑point between the weighted average time to vesting and the contractual maturity. The risk‑free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. There is no expected dividend yield since the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. Net Loss per Share Basic and diluted net loss per share is determined by dividing net loss by the weighted‑average common stock outstanding during the period. Since we have incurred operating losses for all periods presented, outstanding stock options and unvested restricted common stock have been excluded from the calculation because their effects would be anti‑dilutive. Therefore, the weighted‑average shares used to calculate both basic and diluted loss per share are the same. Income Taxes The Company accounts for income taxes under the asset and liability method in accordance with ASC 740, Income Taxes . Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which these temporary differences are expected to be recovered or settled. Valuation allowances are provided if based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Management believes that it is more likely than not that all deferred tax assets will not be realized. The Company recognizes liabilities for potential tax payments to various tax authorities related to uncertain tax positions. The liabilities are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filing is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions, if any, are recorded as components of income tax expense. The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management’s evaluation of the facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the consolidated financial statements. Concentration of Credit Risk and Off-Balance Sheet Risk Financial instruments that subject the Company to credit risk consist primarily of cash, cash equivalents, restricted cash and short-term investments. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and have not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Such deposits have and will continue to exceed federally insured limits. The Company has not experienced any losses on its cash deposits. At December 31, 2021 and 2020 , the Company had no off-balance sheet risk. Foreign Exchange As a result of certain intercompany transactions in September 2021, the Company has determined that the functional currency for AlloVir International and AlloVir Italia is the U.S. Dollar (“USD”). Prior to this determination, the functional currency of AlloVir International and Allovir Italia was the Euro; however, due to the immateriality of the transactions that occurred at AlloVir International and AlloVir Italia previously, the impact of the determination for the transition from Euro to USD is not material and is not considered a change in accounting principle for reporting purposes. Reporting currency has been and remains the USD. Prior to the change in functional currency for AlloVir International and AlloVir Italia, assets and liabilities were translated into USD at the exchange rate in effect on the balance sheet date. Equity balances, other than retained earnings, were translated at historical exchange rates. Income items and expenses were translated at the average exchange rate in effect during the period. Unrealized translation gains and losses were recorded as a cumulative translation adjustment in the consolidated balance sheets. Transactions in foreign currencies are remeasured into the functional currency of the relevant subsidiaries at the exchange rate in effect at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the functional currency at exchange rates in effect at the balance sheet date or on settlement. Resulting gains and losses are recorded in "other income (loss), net" within the consolidated statements of operations and comprehensive loss. Comprehensive Loss Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. Comprehensive loss includes net loss and certain changes in stockholder’s deficit that are excluded from net loss. The Company had a net change in available-for-sale securities and a foreign currency translation adjustment during the years ended December 31, 2021 and 2020, which met the criteria as other comprehensive income and, therefore, the Company’s comprehensive loss includes unrealized gains (losses) on those available-for-sale securities and foreign currency translation adjustments from foreign subsidiaries prior to the change in functional currency for AlloVir International and AlloVir Italia Leases Effective January 1, 2019 , the Company adopted and accounts for its leases under ASC 842, Leases (“ASC 842”), using the modified retrospective transition approach, as applied to the earliest comparative period presented. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease. Leases with a term greater than one year are recognized on the consolidated balance sheet as a right-of-use (“ROU”) asset and current and non-current lease liabilities, as applicable. The Company has made an accounting policy election, known as the short-term lease recognition exemption, which allows the Company to not recognize ROU assets and lease liabilities that arise from short-term leases (12 months or less) for any class of underlying asset. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew or options to cancel a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew or will not cancel, respectively. The Company monitors its leases on a quarterly basis. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected remaining lease term. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense. Certain adjustments to the ROU asset may be required for items such as lease prepayments or incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. The Company has elected to account for the lease and non-lease components together for all existing classes of underlying assets. Subsequent Events The Company evaluates events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. The Company did not identify any material subsequent events requiring adjustment to our accompanying consolidated financial statements (recognized subsequent events). Those items requiring disclosure (unrecognized subsequent events) in the consolidated financial statements have been disclosed accordingly. Refer to Note 17 for further details. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”), or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s consolidated financial statements upon adoption. Under the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with certain new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. As noted below, certain new or revised accounting standards were early adopted. Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12 – Income Taxes (Topic 740) (“ASU 2019-12”), which removes certain exceptions from the guidance and simplifies the accounting for income taxes in certain areas. The Company adopted ASU 2019-12 on January 1, 2021 . There was no material impact to the Company’s consolidated financial statements as a result of adopting this new standard. Recently Issued Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326) : Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 significantly changes the impairment model for most financial assets and certain other instruments. ASU 2016-13 will require immediate recognition of estimated credit losses expected to occur over the remaining life of many financial assets, which will generally result in earlier recognition of allowances for credit losses on loans and other financial instruments. ASU 2016-13 is effective for the Company’s fiscal year beginning after December 15, 2022 and subsequent interim periods. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements and related disclosures. |
Short-Term Investments
Short-Term Investments | 12 Months Ended |
Dec. 31, 2021 | |
Investments, Debt and Equity Securities [Abstract] | |
Short-Term Investments | 3. Short-Term Investments The following tables summarize the amortized cost and estimated fair value of the Company’s marketable securities, which are considered to be available-for-sale investments and were included in short-term investments on the consolidated balance sheets: December 31, 2021 (in thousands) Amortized Unrealized Unrealized Fair U.S. government treasury securities $ 25,092 $ — $ ( 20 ) $ 25,072 Marketable securities: Commercial paper 11,568 1 — 11,569 Corporate bonds 9,821 — ( 3 ) 9,818 Totals $ 46,481 $ 1 $ ( 23 ) $ 46,459 December 31, 2020 (in thousands) Amortized Unrealized Unrealized Fair U.S. government treasury securities $ 233,687 $ — $ ( 24 ) $ 233,663 Totals $ 233,687 $ — $ ( 24 ) $ 233,663 Certain short-term debt securities with original maturities of less than three months are included in cash and cash equivalents on the consolidated balance sheets and are not included in the tables above. At December 31, 2021 and 2020 , all investments had contractual maturities within one year. |
Fair Value Measurements
Fair Value Measurements | 12 Months Ended |
Dec. 31, 2021 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | 4. Fair Value Measurements The following tables present information about the Company’s financial assets measured at fair value on a recurring basis: December 31, 2021 (in thousands) Level 1 Level 2 Level 3 Total Cash equivalents: Money market fund $ 141,378 $ — $ — $ 141,378 Marketable securities: Commercial paper — 7,998 — 7,998 Corporate bonds — 753 — 753 Totals $ 141,378 $ 8,751 $ — $ 150,129 Short-term investments: U.S. government treasury securities $ 25,072 $ — $ — $ 25,072 Marketable securities: Commercial paper — 11,569 $ — 11,569 Corporate bonds — 9,818 — 9,818 Totals $ 25,072 $ 21,387 $ — $ 46,459 December 31, 2020 (in thousands) Level 1 Level 2 Level 3 Total Cash equivalents: Money market fund $ 55,505 $ — $ — $ 55,505 U.S. government treasury securities 39,998 — — 39,998 Totals $ 95,503 $ — $ — $ 95,503 Short-term investments: U.S. government treasury securities $ 233,663 $ — $ — $ 233,663 Totals $ 233,663 $ — $ — $ 233,663 During the years ended December 31, 2021 and 2020, there were no transfers between levels. The Company classifies its money market fund and U.S. government treasury securities as Level 1 assets under the fair value hierarchy, as these assets have been valued using quoted market prices in active markets without any valuation adjustment. The Company classifies its marketable securities (corporate bonds and commercial paper) as Level 2 assets under the fair value hierarchy, as these assets have pricing inputs that are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined using models or other valuation methodologies. The carrying amounts of prepaid expenses and other current assets, accounts payable, amount due to related party and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. |
Leases
Leases | 12 Months Ended |
Dec. 31, 2021 | |
Leases [Abstract] | |
Leases | 5. Leases Short-term leases The Company leases an office space in Houston, Texas under an operating lease that expires in September 2022 . The Company also sub-leased, on a month-to-month basis, a portion of ElevateBio's office space in Cambridge, Massachusetts, which terminated effective January 31, 2022 . During the years ended December 31, 2021 and 2020 , total short-term lease expense recognized was $ 0.4 million (of which approximately $ 37.5 thousand relates to non-lease costs, such as utilities and cleaning), and $ 0.4 million (of which approximately $ 58.2 thousand relates to non-lease costs such as utilities and cleaning), respectively. In April 2021 , the Company entered into a Statement of Work (“SOW”) with a third-party supplier under the Development and Manufacturing Services Agreement (“DMS Agreement”) made effective in July 2019 . This SOW is to lease a dedicated manufacturing suite for the manufacture of AlloVir’s products at the facility. On July 30, 2021, the Company provided a notification to reduce capacity to the third-party supplier which terminates this lease agreement in the first quarter of 2022. During the years ended December 31, 2021 and 2020 , total lease expense recognized under this SOW was $ 0.5 million and $ 0 , respectively. Operating leases Operating lease liabilities and their corresponding right-of-use ("ROU") assets are recorded based on the present value of future lease payments over the expected remaining lease term. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company uses an incremental borrowing rate based on information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate represents the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The Company estimates this rate based on prevailing market conditions, comparable company and credit analysis, the impact of collateralization, and the term of each of the Company’s lease agreements. In March 2019, the Company entered into an interim services agreement which ultimately led to a DMS Agreement with a third-party supplier in July 2019. The DMS Agreement specifies a dedicated manufacturing suite for the manufacture of AlloVir’s products at the facility. The DMS Agreement will expire upon the later of: 1) two years from the Effective Date, or July 2021 , and 2) the completion of services under all SOWs. The term may be extended by agreement of the parties for additional two-year periods upon written notice to the supplier at least 30 days prior to expiration of the then-current term. The DMS Agreement (or any individual SOW) may be terminated earlier by AlloVir at any time by providing 190 days’ notice. The Company has extended the DMS Agreement, and estimates that early termination is not reasonably certain to occur. The total estimated lease term of approximately 4.25 years expires in July 2023 . In March 2019, at the inception of this lease, the Company recorded a ROU asset and lease liability of $ 6.9 million. In September 2019, the Company ex ecuted a SOW for another dedicated manufacturing suite under the DMS Agreement with substantially the same terms as the original SOW. In September 2019, at the inception of this lease, the Company recorded a ROU asset and lease liability of $ 6.3 million. The SOW calls for a fixed monthly payment through July 2023 , with additional two-year renewal options. The total estimated lease term of approximately 3.75 years expires in July 2023 . The use of these manufacturing suites qualify as a lease under ASC 842, as it includes an identified asset for exclusive use by the Company at its direction. In May 2020, the Company entered into a new Development and Manufacturing Services Agreement (“2020 DMS Agreement”) with ElevateBio BaseCamp, Inc. and signed a SOW in November 2020. The 2020 DMS Agreement and related SOW contained an embedded lease for a dedicated manufacturing suite for the manufacture of AlloVir’s products at the facility because the Company directs how and for what purpose the suite is used for and obtains substantially all of the economic benefit of the suite. In exchange for this dedicated manufacturing suite, AlloVir will pay the supplier a monthly fixed suite utilization fee, and other related fixed costs, totaling $ 3.2 million over the two-year lease term ( one year lease with a one-year renewal option), that covers costs associated with reserving capacity for AlloVir, as well as cleaning services, utilities, handling and maintenance of the manufacturing suite. The Company estimates that the exercise of the one-year renewal option is reasonably certain to occur, and the Company is reasonably certain that it will not exercise its early termination right, providing for a total estimated lease term of two years expiring in January 2023 . As part of the arrangement, there were also variable costs for materials, non-fixed batch payments, storage, knowledge and tech transfer and other common area maintenance fees that were not included in the measurement of the lease. The lease of the facility was determined to be classified as an operating lease and commenced in February 2021, the point at which the new facility area was substantially complete and available for use by the Company. Accordingly, at inception, the Company recorded a ROU asset of $ 3.1 million and a lease liability of $ 2.5 million. The Company prepaid $ 0.6 million of the suite utilization fee, which was reclassified from prepaid expense to the ROU asset upon lease commencement. In September 2021, the Company entered into a new lease agreement with BP Bay Colony LLC and a sublease with AMAG Pharmaceuticals Inc. for the lease of property in Waltham, Massachusetts (collectively, the "Waltham leases"). The space identified under the Waltham leases is intended for general office space, research and development, laboratory use, and light manufacturing. The Waltham leases have been classified as operating leases and commenced in September 2021 . At the inception date, the Company has recorded an ROU asset and lease liability of $ 6.0 million for the lease and a ROU asset and lease liability of $ 17.3 million for the sublease based on a July 30, 2030 end date for the Waltham leases. As part of the arrangement, there were also variable costs for common area maintenance fees that were not included in the measurement of the lease. The agreement also provides a $ 3.1 million tenant improvement allowance which is to be reimbursed by the landlord over the duration of the first two years of the Waltham leases. As of December 31, 2021 no allowances have been used and therefore no reduction to the tenant improvement allowance has been made. The Company will monitor the timing of the reimbursements and adjust the ROU asset and lease liability at such time. The Company has the option to renew the leased space for an additional one time period of five years with written notice from the Company. As of December 31, 2021 , the Company has no reasonable certainty that this option to extend will be exercised. Maturities of operating lease liabilities at December 31, 2021 are as follows (in thousands): 2022 $ 7,767 2023 5,273 2024 3,177 2025 3,255 2026 3,334 Thereafter 13,247 Total lease payments 36,053 Less: interest ( 3.40 % - 5.75 %) ( 5,987 ) Total lease liability $ 30,066 Lease liability – current $ 6,591 Lease liability – long-term $ 23,475 Total lease costs were $ 6.2 million and $ 4.0 million for the years ended December 31, 2021 and 2020 , respectively. Cash paid for operating leases was $ 5.2 million and $ 3.6 million for the year ended December 31, 2021 and 2020, respectively. The Company’s total variable non-lease costs, such as materials, non-fixed batch payments, storage, tech transfer and other common area maintenance fees, related to the operating leases was $ 14.5 million and $ 4.5 million for the years ended December 31, 2021 and 2020, respectively. The weighted average remaining lease term is 7.17 years at December 31, 2021 . The weighted average discount rate is 4.96 %. |
Property and Equipment, Net
Property and Equipment, Net | 12 Months Ended |
Dec. 31, 2021 | |
Property, Plant and Equipment [Abstract] | |
Property and Equipment, Net | 6. Property and Equipment, Net Property and equipment, net consisted of the following: December 31, (in thousands) 2021 2020 Laboratory equipment $ 1,395 $ 368 Computer equipment 435 — Construction-in-progress — 536 Total property and equipment 1,830 904 Less: accumulated depreciation ( 281 ) ( 92 ) Property and equipment, net $ 1,549 $ 812 Depreciation expense was $ 0.2 million and $ 0.1 million for the years ended December 31, 2021 and 2020 , respectively. |
Accrued Expenses
Accrued Expenses | 12 Months Ended |
Dec. 31, 2021 | |
Payables and Accruals [Abstract] | |
Accrued Expenses | 7. Accrued Expenses Accrued expenses consisted of the following: December 31, (in thousands) 2021 2020 Employee compensation and benefits $ 6,867 $ 3,314 Professional fees 738 696 Research and development 3,573 1,797 Process development and manufacturing costs 7,685 1,550 Other 1,289 173 Total accrued expenses $ 20,152 $ 7,530 |
Sponsored Research, Collaborati
Sponsored Research, Collaboration and License Agreements | 12 Months Ended |
Dec. 31, 2021 | |
Research and Development [Abstract] | |
Sponsored Research, Collaboration and License Agreements | 8. Sponsored Research, Collaboration and License Agreements Amended and Restated Exclusive License Agreement with BCM In June 2017, the Company signed a License Agreement (the “License Agreement”) with BCM, whereby the Company acquired a royalty-bearing, worldwide, exclusive license to BCM’s rights in Subject Technology and related patent rights in the field of viral infection. In May 2020, the Company amended and restated the License Agreement (the “A&R License Agreement”), pursuant to which the Company obtained (a) an exclusive worldwide license, with the right to sublicense, under certain patent rights and other intellectual property rights of BCM, to make, have made, use, market, sell, offer to sell, lease, import and export products in a particular field, except that such license is non-exclusive within a particular subfield, and in addition with respect to certain patent rights such license is limited to two particular subfields, and (b) an exclusive, worldwide sublicense, with the right to further sublicense, under all patent rights and other intellectual property rights that are exclusively licensed to BCM by a certain third party licensor, to make, have made, use, market, sell, offer to sell, lease, import and export products in the same field. The Company’s rights are subject to the rights of the U.S. government and certain rights retained by BCM. Unless earlier terminated, the A&R License Agreement will expire on a country-by-country basis with respect to a product upon the later of (a) the expiration of the last to expire valid claim of a patent or patent application covering such product in such country or (b) 10 years after the first commercial sale of such product in such country. The Company may terminate the A&R License Agreement in its entirety at any time for convenience upon a certain number of days’ written notice. BCM may terminate the A&R License Agreement in its entirety for the Company’s uncured material default. BCM maintains control of all filing, prosecution and maintenance of its patent rights licensed by the Company, and the Company is responsible for all related costs and expenses during the term of the agreement. The Company also reimbursed BCM for costs and expenses (including reasonable legal fees and expenses) incurred prior to the effective date of the agreement with respect to the filing, prosecution and maintenance of the patent rights licensed by the Company. If BCM licenses the patent rights licensed by the Company to third parties for additional fields of use, the Company’s responsibility for patent related costs and expenses will be reduced on a pro-rata basis. Under the A&R License Agreement, the Company must use commercially reasonable efforts to develop and commercialize one or more products in certain countries. As partial consideration for the rights conveyed by BCM under the original agreement executed in June 2017, the Company paid BCM a non-refundable license fee of $ 250,000 . During the term of the A&R License Agreement, the Company is obligated to pay BCM a non-refundable annual license maintenance fee, but beginning with the fifth year after the original agreement date, license maintenance fees are fully creditable against royalty revenue due in the applicable year. The Company is required to pay certain milestone payments upon the achievement of specified clinical, regulatory, and sales milestones. In the event that the Company is able to successfully develop, launch and commercialize a product under the A&R License Agreement, total milestone payments could exceed $ 40.0 million. BCM is also eligible to receive tiered royalties at percentage rates ranging from less than 1 % to the low single-digits, on net sales of any products that are commercialized by the Company or its sublicensees that incorporate, utilize or are made with the use of, the intellectual property licensed by the Company. To the extent the Company sublicenses its license rights under the A&R License Agreement, BCM would be eligible to receive tiered sublicense income at percentage rates in the mid-single to low double-digits. In November 2020, the Company also entered into the First Amendment (the “License Amendment”) to the A&R License Agreement. Under the License Amendment, the Company assumed responsibility from BCM for the filing, prosecution and maintenance of the patent rights licensed by the Company from BCM under the A&R License Agreement that are in common with the License Agreement. Further, BCM also transferred to the Company the right of enforcement against third parties for any suspected infringement of any claims in such patent rights or misuse, misappropriation, theft or breach of confidence of other proprietary rights. Exclusive License Agreement with BCM In November 2020, the Company signed a second License Agreement (the “Second License Agreement) with BCM, whereby the Company acquired a royalty-bearing, worldwide, exclusive license to BCM’s rights in Subject Technology and related patent rights outside the field of viral infection (all fields other than those covered by the A&R License Agreement). Unless earlier terminated, the Second License Agreement will expire on a country-by-country basis with respect to a product upon the later of (a) the expiration of the last to expire valid claim of a patent or patent application covering such product in such country or (b) 10 years after the first commercial sale of such product in such country, provided that the Second License Agreement shall not expire later than March 25, 2040. The Company may terminate the Second License Agreement in its entirety at any time for convenience upon a certain number of days’ written notice. BCM may terminate the Second License Agreement in its entirety for the Company’s uncured material default. Under the Second License Agreement, BCM transferred to the Company control of all filing, prosecution and maintenance of the patent rights licensed by the Company, and the Company is responsible for all related costs and expenses during the term of the Second License Agreement. BCM also transferred to the Company the right of enforcement against third parties for any suspected infringement of any claims in the patent rights or misuse, misappropriation, theft or breach of confidence of other proprietary rights. The Company also reimbursed BCM for costs and expenses (including reasonable legal fees and expenses) incurred prior to the effective date of the Second License Agreement with respect to the filing, prosecution and maintenance of the patent rights licensed by the Company, to the extent not already paid by the Company under the A&R License Agreement. Under the Second License Agreement, the Company must use commercially reasonable efforts to develop and commercialize one or more products in certain countries. As partial consideration for the rights conveyed by BCM under the Second License Agreement, the Company paid BCM a non-refundable license fee of $ 125,000 . During the term of the Second License Agreement, the Company is obligated to pay BCM a non-refundable annual license maintenance fee of (a) $ 20,000 for the first through fourth anniversary of the effective date of the Second License Agreement, and (b) $ 40,000 for the fifth anniversary of the effective date and continuing thereafter, but beginning with the fifth year, license maintenance fees are fully creditable against royalty revenue due in the applicable year. The Company is required to pay certain milestone payments upon the achievement of specified clinical, regulatory, and sales milestones. In the event that the Company is able to successfully develop, launch and commercialize multiple products under the Second License Agreement, total milestone payments could exceed $ 30.0 million. BCM is also eligible to receive tiered royalties at percentage rates ranging from less than 1 % to the low single-digits, on net sales of any products that are commercialized by the Company or its sublicensees that incorporate, utilize or are made with the use of, the intellectual property licensed by the Company. To the extent the Company sublicenses its license rights under the Second License Agreement, BCM would be eligible to receive tiered sublicense income at percentage rates in the mid-single to low double-digits. Sponsored Research Agreement with BCM In June 2019, the Company entered into a sponsored research agreement (“SRA-2”) with BCM, under which the Company agreed to pay BCM for performing certain research activities related to virus specific T-cell manufacturing for a one-year period, renewable for an additional one-year term upon written consent of both parties. SRA-2 requires the Company to make payments to BCM totaling $ 1.0 million, payable in four equal installments. SRA-2 was amended in March 2020 to include the discovery and development of allogeneic, off-the-shelf, virus specific T-cell therapies to combat SARS-CoV-2, the virus that causes COVID-19. In June 2020, a second amendment was entered into resulting in a no cost extension through November 30, 2020, upon which the agreement terminated. Collaboration Agreement with BCM In November 2020, the Company also entered into a Research Collaboration Agreement (the “Research Agreement”) with BCM, under which the Company agreed to pay BCM for performing certain research activities under the direction of Dr. Ann Leen commencing on January 1, 2021 and continuing for a three-year period thereafter. The Research Agreement requires the Company to make payments to BCM totaling approximately $ 2.0 million per year, for a total of approximately $ 6.0 million over the term of the Research Agreement. Collectively under the agreements above and for services provided by BCM the Company paid $ 3.3 million and $ 1.1 million during the years ended December 31, 2021 and 2020 , respectively, and the payments were classified in research and development expense in the consolidated statements of operations and comprehensive loss. The Company has also triggered three milestone events during the year ended December 31, 2021 and has accounted for $ 0.2 million in accrued milestone expenses which are classified under accrued expenses in the condensed consolidated balance sheet. CPRIT Grant In August 2017, the Company was awarded a $ 9.0 million grant (the “CPRIT Grant”) from the Cancer Research and Prevention Institute of Texas (“CPRIT”) to perform a phase IIB clinical trial to establish the safety and effectiveness of posoleucel, in adults and children with a common, very severe virus infection (BK Virus) after stem cell transplant. The grant period was three years beginning September 1, 2017 through August 31, 2020. This grant had a matching requirement where the Company was obligated to match 50 % of the grant funds used on the project. In addition, the grant included other compliance requirements including the obligation for the Company to operate with a principal place of business in Texas. There were no costs incurred to obtain or fulfill the contract. In November 2019, the Company provided CPRIT with written notice of its intent to terminate the grant. In December 2019, the Company returned $ 2.6 million of grant funds received, including interest relating to these funds in the amount of $ 0.1 million, and decreased its deferred revenue balance to zero . The Company received acknowledgment of the termination from CPRIT in January 2020. The CPRIT Grant also required that the Company grant CPRIT a non-commercial license to technology developed under the grant and pay CPRIT a share of revenue on sales of commercial products developed using CPRIT funds equal to low single digits of revenue until such time as CPRIT has been paid an aggregate amount equal to 400 % of the grant award proceeds. No royalty payments were made under this license agreement during the years ended December 31, 2021 and 2020 , respectively. |
Funding Arrangements
Funding Arrangements | 12 Months Ended |
Dec. 31, 2021 | |
Research and Development [Abstract] | |
Funding Arrangements | . Funding Arrangements SBIR Grant In June 2017, the Company was awarded a Small Business Innovation Research (“SBIR”) grant by the National Institute of Health (“NIH”) in the amount of $ 3.0 million. This grant was effective from September 15, 2017 to June 30, 2020 and in April 2020, the Company received an extension through June 30, 2021. The grant was funded on an ongoing basis based on periodic reports of qualifying expenditures reported by the Company to NIH. Under this grant, the Company received proceeds of $ 0 and $ 0.9 million during the years ended December 31, 2021 and 2020 , respectively. The Company recognized income of $ 0 and $ 0.6 million on expenses incurred during the years ended December 31, 2021 and 2020, respectively. At December 31, 2020, the Company had received the full amount awarded under the SBIR grant. The grant was not extended past June 30, 2021 and the Company notified the NIH of grant completion in July 2021. The SBIR grant does not fall within the scope of ASC 606 as NIH does not meet the definition of a customer, and the grant from NIH was given for the benefit of public health rather than for monetary compensation. Accordingly, funding received under this grant is recognized in “Other income (loss), net” in the consolidated statements of operations and comprehensive loss. |
Stockholder's Equity
Stockholder's Equity | 12 Months Ended |
Dec. 31, 2021 | |
Equity [Abstract] | |
Stockholder's Equity | 10. Stockholder’s Equity On August 3, 2020, in connection with the closing of the Company’s IPO, the Company filed its amended and restated certificate of incorporation, which authorizes the Company to issue up to 10,000,000 shares of preferred stock, $ 0.0001 par value per share. There were no shares of preferred stock issued or outstanding at December 31, 2021 and 2020. At December 31, 2021 and 2020 , the Company’s amended and restated certificate of incorporation authorized the Company to issue 150,000,000 shares of common stock at a par value of $ 0.0001 per share. In conjunction with the Company's IPO closing on August 3, 2020, the Company issued and sold 18,687,500 shares of its common stock, including 2,437,500 shares pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $ 17.00 per share, for aggregate net proceeds of $ 292.0 million after deducting underwriting discounts and commissions and offering costs. In connection with the Company’s IPO, all outstanding shares of preferred stock converted into 39,859,139 shares of common stock. The following is a summary of the rights and privileges of the holders of the Company’s common stock at December 31, 2021 and 2020: Voting Rights The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders (and written actions in lieu of meetings), and there are not any cumulative voting rights. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of shares of capital stock of the Company; however, the issuance of common stock may be subject to the vote of the holders of one or more series of preferred stock that may be required by terms of the Third Amended and Restated Certificate of Incorporation. Dividends Subject to preferences that may be applicable to any then-outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the Board out of legally available funds. At December 31, 2021 , no cash dividends have been declared or paid. Liquidation Preference In the event of a liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all debts and other liabilities and the satisfaction of any liquidation preference granted to the then-outstanding shares of preferred stock. Rights and Preferences Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that the Company may designate in the future. The Company has reserved shares of common stock for issuance as follows: December 31, 2021 2020 Unvested restricted stock 2,866,909 3,410,979 Options to purchase common stock 6,155,055 3,972,909 Stock available for grant under the 2020 Stock Option and Grant Plan 3,812,396 3,895,961 Total 12,834,360 11,279,849 |
Stock-Based Compensation
Stock-Based Compensation | 12 Months Ended |
Dec. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Stock-Based Compensation | 11. Stock-Based Compensation 2018 Equity Incentive Plan The Company’s 2018 Plan provided for the Company to issue restricted stock, restricted stock units, incentive stock options, and non-statutory stock options and other stock-based awards to employees, officers, members of the Board, consultants and advisors of the Company. The 2018 Plan was most recently amended in July 2020. The awards granted under this plan generally vest over a four-year period and have a 10-year contractual term. At December 31, 2021 , the Company had granted 6,715,415 shares of common stock under the 2018 Plan, including an aggregate of 64,042 shares of common stock issuable upon the exercise of outstanding options under the 2018 Plan. Of the awards granted, 31,600 awards have been forfeited or cancelled during the year ended December 31, 2021 . No shares remain available for future issuance under the 2018 Plan. Any options or awards outstanding under the 2018 Plan remain outstanding and effective. 2020 Stock Option and Grant Plan On July 2, 2020, the Company’s Board of Directors adopted and in July 2020 the stockholders approved the 2020 Stock Option and Grant Plan (the “2020 Plan”) which became effective on July 28, 2020, the date immediately prior to the date on which the registration statement related to the IPO was declared effective, and as a result no further awards were made under the 2018 Plan thereafter. Initially, the aggregate number of shares of our common stock that may be issued pursuant to stock awards under the 2020 Plan was 8,008,734 shares. The number of shares of our common stock reserved for issuance under the 2020 Plan shall be cumulatively increased on January 1, 2021 and each January 1 thereafter by 5 % of the total number of shares of our common stock outstanding on December 31 of the preceding calendar year or a lesser number of shares determined by our board of directors. Unless our board of directors elects not to increase the number of shares available for future grant each year, our stockholders may experience additional dilution, which could cause our stock price to fall. The awards granted under this plan generally vest over a four-year period and have a 10 -year contractual term. At December 31, 2021 , there were an aggregate of 6,091,013 shares of common stock issuable upon the exercise of outstanding options under the 2020 Plan and 1,443,520 shares of restricted common stock granted under the 2020 Plan. There were an aggregate of 3,812,396 shares reserved for future issuance under the 2020 Plan at December 31, 2021 . On January 1, 2022, 3,258,517 shares were added to the number of available shares under the 2020 Plan. Restricted Common Stock The following table summarizes restricted common stock activity for the year ended December 31, 2021: Shares Weighted Unvested at January 1, 2021 3,410,979 $ 3.55 Granted 1,192,513 33.61 Forfeited ( 127,104 ) 25.91 Vested ( 1,609,479 ) 2.87 Unvested at December 31, 2021 2,866,909 $ 15.45 During the year ended December 31, 2020, t he weighted average grant date fair value of restricted stock granted was $ 21.07 per share and the weighted average grant date fair value of restricted stock vested was $ 1.84 per share. At December 31, 2021 , there was $ 34.1 million of unrecognized stock-based compensation cost related to the restricted stock, which is expected to be recognized over a weighted average period of 3.01 years. Stock Options The following table summarizes stock option activity (in thousands, except share and per share data): Shares Weighted Weighted Aggregate Options outstanding at January 1, 2021 3,972,909 $ 17.84 9.6 $ 81,822 Granted 2,478,888 32.41 — Exercised ( 25,152 ) 9.25 274 Forfeited ( 271,590 ) 25.31 1,047 Options outstanding at December 31, 2021 6,155,055 $ 23.42 8.8 $ 480 Options vested and exercisable at December 31, 2021 1,310,019 $ 17.87 8.6 $ 294 The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the common stock as of the end of the period. The weighted average grant-date fair value of stock options granted during the years ended December 31, 2021 and 2020 was $ 24.76 per share and $ 13.77 per share, respectively. At December 31, 2021 , there was $ 73.5 million of unrecognized stock-based compensation expense related to unvested stock options, which is being recognized over a period of 2.88 years. The fair value was estimated on the date of grant using the Black-Scholes option-pricing model, with the following weighted-average assumptions: Years Ended December 31, 2021 2020 Expected term (in years) 6.06 6.08 Expected volatility 95 % 95 % Risk-free interest rate 0.87 % 0.36 % Expected dividend yield — — Fair value of common stock $ 32.41 $ 18.08 Stock-Based Compensation Expense Stock-based compensation expense was as follows: Years Ended December 31, (in thousands) 2021 2020 Research and development $ 20,632 $ 3,571 General and administrative 23,343 5,858 Total stock-based compensation expense $ 43,975 $ 9,429 2020 Employee Stock Purchase Plan In July 2020, the 2020 Employee Stock Purchase Plan (the “2020 ESPP”) was also adopted by the Board of Directors and approved by the stockholders. The purpose of the 2020 ESPP is to provide eligible employees of the Company and other designated companies, with opportunities to purchase shares of the Company’s common stock, par value $ 0.0001 per share. 611,354 shares of common stock in the aggregate have been approved and reserved for this purpose, plus on January 1, 2021 and each January 1 thereafter until January 1, 2030, the number of shares of common stock reserved and available for issuance under the Plan shall be cumulatively increased by the least of (i) 1,222,707 shares of common stock, (ii) 1 % of the number of shares of common stock issued and outstanding on the immediately preceding December 31, and (iii) such number of shares of common stock as determined by the Administrator. The Board of Directors elected not to increase the number of available shares as of January 1, 2021 and 2022. |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | 12. Income Taxes The Company accounts for income taxes under the asset and liability method in accordance with ASC 740, Income Taxes. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which these temporary differences are expected to be recovered or settled. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Management believes that it is more likely than not that all deferred tax assets will not be realized. The Company recognizes liabilities for potential tax payments to various tax authorities related to uncertain tax positions. The liabilities are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filing is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions, if any, are recorded as components of income tax expense. The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management’s evaluation of the facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the consolidated financial statements. Income (loss) before provision for income taxes consisted of the following: Years Ended December 31, (in thousands) 2021 2020 Federal 49,045 ( 68,356 ) Foreign ( 220,000 ) ( 1,428 ) Loss before provision for income taxes $ ( 170,955 ) $ ( 69,784 ) The provision for income taxes for the years ended December 31, 2021 and 2020 consisted of the following: Years Ended December 31, (in thousands) 2021 2020 Current income tax expense (benefit): Federal $ 987 — State 20 — Foreign — — Total current income tax expense (benefit) 1,007 — Deferred income tax expense (benefit): Federal — — State — — Foreign — — Total deferred income tax expense (benefit) — — Total income tax expense (benefit) $ 1,007 $ — The Company’s income tax expense (benefit) for the years ended December 31, 2021 and 2020 relating to federal, state and foreign tax jurisdictions differs from the amounts determined by applying the statutory federal income tax rate based on the following: Years Ended December 31, (in thousands) 2021 2020 Benefit at the federal rate $ ( 35,901 ) 21.0 % $ ( 14,655 ) 21.0 % Increase (decrease) resulting from: Foreign tax rate differential 43,786 ( 25.6 )% — — State taxes, net of federal benefit 1,018 ( 0.6 )% ( 1,943 ) 2.8 % Change in valuation allowance 22,268 ( 13.0 )% 17,756 ( 25.4 %) Intellectual property transfer ( 25,538 ) 14.9 % — — Tax credits ( 5,540 ) 3.3 % ( 1,220 ) 1.7 % Officer's compensation 2,648 ( 1.5 )% — — Stock compensation ( 2,464 ) 1.4 % — — Other 730 ( 0.5 )% 62 ( 0.1 )% Total Income Tax Expense (Benefit) $ 1,007 ( 0.6 )% $ — — During the year ended December 31, 2021, the Company transferred intellectual property rights between tax jurisdictions, resulting in a deferred tax benefit on the basis difference in our intangible assets. The additional deferred tax asset was offset by valuation allowance, resulting in no net impact to deferred tax expense (benefit). The transfer of intellectual property rights generated U.S. current income tax expense of $ 1.0 million after utilization of net operating loss and tax credit carryforwards. Components of deferred income taxes consist of the following: December 31, (in thousands) 2021 2020 Deferred tax assets: Net operating loss carryforwards $ 5,460 $ 20,866 Tax credit carryforwards 4,683 2,215 Intangible Assets 25,538 — Operating lease liabilities 6,865 2,244 Non-qualified stock compensation 8,028 1,326 Restricted stock compensation 1,778 — Other 1,646 910 Total deferred tax assets 53,998 27,561 Valuation allowance ( 46,823 ) ( 24,555 ) Net deferred tax asset (liability) $ 7,175 $ 3,006 Deferred tax liabilities: Operating lease right-of-use assets ( 6,791 ) ( 2,244 ) Restricted stock compensation — ( 629 ) Depreciation ( 350 ) ( 65 ) Other ( 34 ) ( 68 ) Total deferred tax liabilities ( 7,175 ) ( 3,006 ) Net deferred tax asset (liability) $ — $ — The Company’s accounting for deferred taxes involves the evaluation of a number of factors concerning the realizability of its net deferred tax assets. The Company primarily considered such factors as its history of operating losses, the nature of the Company’s deferred tax assets, and the timing, likelihood and amount, if any, of future taxable income during the periods in which those temporary differences and carryforwards become deductible. At December 31, 2021 and 2020, the Company does not believe that it is more likely than not that the deferred tax assets will be realized; accordingly, a full valuation allowance has been established and no deferred tax asset is shown in the accompanying consolidated balance sheets. For the year ended December 31, 2021 , the valuation allowance for deferred tax assets increased by $ 22.3 million, which was principally due to net operating losses and tax basis generated from the intellectual property transfer. At December 31, 2021 and 2020 , the Company had unused federal net operating loss carryforwards of $ 13.3 million and $ 88.6 million, respectively. The federal net operating loss carryforwards have no expiration. The CARES Act temporarily allows the Company to carryback net operating losses arising in 2018, 2019 and 2020 to the five prior tax years. In addition, net operating losses generated in these years could fully offset prior year taxable income without the 80 % of the taxable income limitation under the TCJA which was enacted on December 22, 2017. The Company has been generating losses since its inception, as such the net operating loss carryback provision under the CARES Act is not applicable to the Company. At December 31, 2021 and 2020 , the Company had unused state net operating loss carryforwards of $ 8.5 million and $ 31.7 million, respectively. The state net operating loss carryforwards expire in 2035 . At December 31, 2021 and 2020, the Company had unused foreign net operating loss carryforwards of $ 16.8 million and $ 1.3 million, respectively. The foreign net operating loss carryforwards have no expiration. At December 31, 2021 and 2020 , the Company had $ 2.8 million and $ 1.8 million of research and development tax credit carryforwards that may be available to offset future federal income taxes through 2040 . Additionally, at December 31, 2021, the Company had a federal orphan drug credit (ODC) carryforward related to qualifying research of $ 1.3 million that will begin to expire in 2041 . At December 31, 2021 and 2020 , the Company also had $ 0.8 million and $ 0.5 million of research and development tax credit carryforwards that may be available to offset future state income taxes in the state of Massachusetts through 2035 . Utilization of net operating loss and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, as amended, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of net operating loss and research and development tax credit carryforwards that can be utilized annually to offset future taxable income and tax expense, respectively. The Company has completed several financings since its inception which may result in a change of control as defined in Section 382 of the Internal Revenue Code or could result in a change in control in the future. The Company complies with the provisions of ASC 740 in accounting for its uncertain tax positions. ASC 740 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the consolidated financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. At December 31, 2021 and 2020 , the Company had no uncertain tax positions. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in income tax expense. The Company had no accruals for interest and penalties at December 31, 2021 and 2020. The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. The statute of limitations for assessment by the Internal Revenue Service and state tax authorities remains open for the tax years December 31, 2018 through December 31, 2021 as the Company was incorporated in September 2018. There are currently no federal, state or foreign income tax audits in progress. The resolution of tax matters is not expected to have a material effect on the Company's consolidated financial statements. |
Net Loss per Share
Net Loss per Share | 12 Months Ended |
Dec. 31, 2021 | |
Earnings Per Share [Abstract] | |
Net Loss per Share | 13. Net Loss per Share The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company: Years Ended December 31, (in thousands, except share and per share data) 2021 2020 Numerator: Net loss – basic and diluted $ ( 171,962 ) $ ( 69,874 ) Denominator: Weighted-average common shares outstanding – basic and diluted 62,782,126 26,897,390 Net loss per share – basic and diluted $ ( 2.74 ) $ ( 2.59 ) Based on the amounts outstanding at December 31, 2021 and 2020, the Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders for the years ended December 31, 2021 and 2020, because including them would have had an anti-dilutive effect. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. Years Ended December 31, 2021 2020 Options to purchase common stock 6,155,055 3,972,909 Unvested restricted stock 2,866,909 3,410,979 |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 14. Commitments and Contingencies Leases The Company leases an office space in Houston, Texas under an operating lease that expires in September 2022 . The Company also sub-leases from ElevateBio a portion of its office space in Cambridge, Massachusetts on a month-to-month basis, which was terminated effective January 31, 2022 . The Company entered into a new lease agreement and a sublease agreement in 2021 for the lease of property in Waltham, Massachusetts. Se e Note 5 for additional information. Purchase Obligation The Company entered into a DMS Agreement (see Note 5) w hereby the Company is required to purchase at least one batch of product per month for both dedicated manufacturing suites, totaling $ 0.3 million per month, regardless of the Company’s demand. The monthly batch product purchases related to the DMS Agreement will cease in July 2023 . Legal Proceedings From time to time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well as information gathering requests, inquiries and investigations. At December 31, 2021 , there were no matters which would have a material impact on the Company’s financial results. |
Related Party Transactions
Related Party Transactions | 12 Months Ended |
Dec. 31, 2021 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | 15. Related Party Transactions The Company entered into an agreement with ElevateBio that provides for ongoing services to the Company in areas such as accounting operations, public relations, information technology, human resources and administration management, finance and risk management, marketing services, facilities, procurement and travel and corporate development and strategy (the “Shared Services Agreement”). The Company was billed quarterly for such services at cost, with mark-up for profit on specific services, but including reasonable allocations of employee benefits, facilities and other direct or fairly allocated indirect costs that relate to the associates providing the services. The Company also subleases office space, which includes payment for common area charges. The Company also has a SOW to receive manufacturing and project management consulting services from ElevateBio. During the year ended December 31, 2021 , the Company recorded expenses of $ 5.9 million related to services provided to the Company by ElevateBio and affiliates. During the year ended December 31, 2020 , the Company recorded expenses of $ 7.3 million, including services that were to be provided of $ 0.9 million related to services provided to the Company by ElevateBio and affiliates. The Company owed ElevateBio $ 1.7 million and $ 0.6 million at December 31, 2021 and 2020, respectively, which is recorded in “Amount due to related party” on the consolidated balance sheets. Members of the Company’s management received a total of $ 0.5 million and $ 0.6 million in consulting fees during the years ended December 31, 2021 and 2020 , respectively. |
Employee Benefit Plans
Employee Benefit Plans | 12 Months Ended |
Dec. 31, 2021 | |
Retirement Benefits [Abstract] | |
Employee Benefit Plans | 16. Employee Benefit Plans Effective January 1, 2019, the Company adopted a 401(k) Plan for its employees, which is designed to be qualified under Section 401(k) of the Internal Revenue Code. Eligible employees are permitted to contribute to the 401(k) Plan within statutory and 401(k) Plan limits. The Company made matching contributions of $ 0.5 million and $ 0.1 million for the years ended December 31, 2021 and 2020 , respectively. |
Subsequent Events
Subsequent Events | 12 Months Ended |
Dec. 31, 2021 | |
Subsequent Events [Abstract] | |
Subsequent Events | 17. Subsequent Events For the financial statements at December 31, 2021 and for the year then ended, the Company has evaluated all subsequent events through February 10, 2022, the date the consolidated financial statements were available to be issued, noting there were no events or matters identified that require additional disclosure. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Basis of Presentation and Consolidation | Basis of Presentation and Consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The consolidated financial statements include the Company’s accounts and those of its wholly-owned subsidiaries. All intercompany accounts, transactions and balances have been eliminated in consolidation. |
Segment Information | Segment Information Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has one operating segment. The Company’s singular focus is the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purpose of allocating resources. All of the Company’s long-lived assets are held in the United States. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates. |
Cash and Cash Equivalents | Cash and Cash Equivalents Cash and cash equivalents are short-term, highly liquid investments with original maturities of three months or less at the date of purchase. Investments qualifying as cash equivalents primarily consist of money market funds, corporate bonds and commercial paper. |
Short-Term Investments | Short-Term Investments Short-term investments consist of U.S. treasury securities, corporate bonds and commercial paper classified as available-for-sale that have maturities of less than one year . Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive income (loss). The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization or accretion is included in "other income (loss), net". The cost of securities sold is based on the specific identification method. Interest on debt securities classified as available-for-sale are included in interest income. To determine whether an other-than-temporary impairment exists, the Company considers whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability of the cost of the investment outweighs evidence to the contrary. There were no individual securities with impairments at December 31, 2021 and 2020 . |
Restricted Cash | Restricted Cash Cash accounts with any type of restriction are classified as restricted cash. The Company has restricted cash deposits with a bank, which serve as collateral for a letter of credit issued to the landlord of the Company’s leased Waltham facility for a security deposit. The Company classified this amount as non-current restricted cash in the accompanying condensed consolidated balance sheet at December 31, 2021 . There was no restricted cash balance at December 31, 2020 . |
Property and Equipment, Net | Property and Equipment, Net The Company records property and equipment at cost and recognizes depreciation using the straight-line method over the estimated useful lives of the respective assets , as follows: Asset category Estimated useful life Computer equipment 3 years Laboratory equipment 5 years The Company periodically evaluates whether events and circumstances have occurred that may warrant revision of the estimated useful life of property and equipment. Expenditures for repairs and maintenance of assets are expensed as incurred. Upon retirement or sale, the cost of assets disposed and the corresponding accumulated depreciation are removed from the related accounts and any resulting gain or loss is reflected in the results of operations. Construction in progress is not depreciated until it is placed in service. Property and equipment to be disposed of are carried at fair value less costs to sell. |
Impairment of Long-Lived Assets | Impairment of Long-Lived Assets The Company accounts for long-lived assets in accordance with ASC Topic 360, Property, Plant, and Equipment (“ASC 360”). ASC 360 requires companies to: (i) recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and (ii) measure an impairment loss as the difference between the carrying amount and the fair value of the asset. The Company tests long-lived assets to be held and used, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of assets or asset groups may not be fully recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. The Company has no t recognized any impairment losses during the years ended December 31, 2021 and 2020 . |
Fair Value Measurements | Fair Value Measurements ASC Topic 820, Fair Value Measurement (“ASC 820”), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes among the following: • Level 1 – Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. • Level 2 – Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. • Level 3 – Valuations based on inputs that are unobservable and significant to the overall fair value measurement. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company’s financial instruments include cash equivalents, short-term investments, accounts payable, amount due to related party and accrued expenses. Certain of the Company’s financial assets, including cash equivalents and short-term investments, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models and observable market inputs to determine value. Other financial instruments, including accounts payable, amount due to related party and accrued expenses, are carried at cost, which approximate fair value due to the short duration and term to maturity. |
Deferred Offering Costs | Deferred Offering Costs The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are presented in the consolidated balance sheets as a direct reduction from the carrying amount of the respective equity instrument issued. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss. Upon closing the IPO in August 2020, deferred offering costs were derecognized and recorded against the IPO proceeds as a debit to additional paid-in capital. At December 31, 2021 and 2020 , the Company had no deferred offering costs. |
Cloud Computing Arrangements | Cloud Computing Arrangements The Company capitalizes certain implementation costs for internal-use software incurred in a cloud computing agreement that is a service contract. Eligible costs associated with cloud computing arrangements, such as the implementation costs incurred to develop or obtain software business applications used in the normal course of business, are capitalized in accordance with ASC 350. Capitalization ceases at the point the software is substantially complete and ready for its intended use, and after all substantial testing is completed. Amortization is recorded on a straight-line basis over the expected useful life of three years of the internal-use software cost in the same line item in the statement of operations and comprehensive loss as the expense for fees for the associated cloud computing arrangement. Amortization expense associated with the Company's cloud computing arrangements has been recognized in the amount of $ 0.1 million and $ 0 during the years ended December 31, 2021 and 2020 . |
Other Income (Loss), Net | Other Income (Loss), Net The Company records interest expense, investment amortization and accretion and other government grants, not considered customers under ASC 606, in “other income (loss), net” over the same period in which the qualifying costs are incurred. Proceeds received from other government grants prior to the costs being incurred or the conditions of the award being met are recognized as deferred grant income until the services are performed and the conditions of the grant are met. To the extent that qualifying costs have been incurred prior to receipt of funds, the Company records an unbilled grant receivable upon recognition of those expenses. |
Research and Development Costs | Research and Development Costs Research and development costs are charged to expense as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, stock-based compensation, facilities, research-related overhead, clinical trial costs, contracted services, research-related manufacturing, license fees and other external costs. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the services have been performed or when the goods have been received. |
Accrued Research and Development Expenses | Accrued Research and Development Expenses The Company has entered into various research and development contracts. The payments under these contracts are recorded as research and development expenses as incurred. The Company records accrued liabilities for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Judgements and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. The Company’s historical accrual estimates have not been materially different from the actual costs. |
Research and Development Grants | Research and Development Grants Grants are recognized as a rec eivable at their fair value when there is reasonable assurance that the grant will be received and the Company will comply with all the attached conditions. Grants receivable are recognized on a systematic basis as income over the periods necessary to match them with the related costs which they are intended to compensate. Grants that have been earned, other than those grants that fall under ASC 606, where the Company determined that the grantor is a customer, are presented in the consolidated statements of operations and comprehensive loss as “other income (loss), net”. |
Stock-Based Compensation Expense | Stock-Based Compensation Expense The Company grants restricted stock and stock options to employees, consultants and directors. The Company recognizes stock-based compensation cost for awards with performance conditions if and when it concludes that it is probable that the performance conditions will be achieved. For awards with only a service condition, the Company expenses stock-based compensation on a straight-line basis over the requisite employee service period or for grants issued with performance conditions, on a graded-vesting basis over the requisite employee service period. Awards for employees and non-employees are accounted for similarly. The Company records stock-based compensation expense associated with grants of restricted stock and stock options in the consolidated statements of operations and comprehensive loss based on their estimated fair value at the date of the grant. The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the grantee’s payroll costs are classified or in which the grantee’s service payments are classified. Forfeitures are accounted for as they occur. The fair value of each stock option grant is estimated on the date of grant using the Black‑Scholes option pricing model. As there was no public market for the Company’s common stock prior to the initial public offering of its common stock in August 2020, the estimated fair value of common stock was determined by the Company’s board of directors as of the date of each option grant, with input from management, considering third-party valuations of its common stock, as well as the Company’s board of directors’ assessment of additional objective and subjective factors that it believed were relevant, and which may have changed from the date of the most recent third-party valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants’ Accounting and Valuation Guide, Valuation of Privately Held Company Equity Securities Issued as Compensation. Following the closing of the initial public offering, the fair value of the Company’s common stock is determined based on the quoted market price of common stock. The Company also lacks company‑specific historical and implied volatility information for its stock. The Company estimates its expected stock price volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company’s stock options has been determined utilizing the “simplified” method. The “simplified” method estimates the expected term of stock options as the mid‑point between the weighted average time to vesting and the contractual maturity. The risk‑free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. There is no expected dividend yield since the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. |
Net Loss Per Share | Net Loss per Share Basic and diluted net loss per share is determined by dividing net loss by the weighted‑average common stock outstanding during the period. Since we have incurred operating losses for all periods presented, outstanding stock options and unvested restricted common stock have been excluded from the calculation because their effects would be anti‑dilutive. Therefore, the weighted‑average shares used to calculate both basic and diluted loss per share are the same. |
Income Taxes | Income Taxes The Company accounts for income taxes under the asset and liability method in accordance with ASC 740, Income Taxes . Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which these temporary differences are expected to be recovered or settled. Valuation allowances are provided if based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Management believes that it is more likely than not that all deferred tax assets will not be realized. The Company recognizes liabilities for potential tax payments to various tax authorities related to uncertain tax positions. The liabilities are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filing is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions, if any, are recorded as components of income tax expense. The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management’s evaluation of the facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the consolidated financial statements. |
Concentration of Credit Risk and Off-Balance Sheet Risk | Concentration of Credit Risk and Off-Balance Sheet Risk Financial instruments that subject the Company to credit risk consist primarily of cash, cash equivalents, restricted cash and short-term investments. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and have not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Such deposits have and will continue to exceed federally insured limits. The Company has not experienced any losses on its cash deposits. At December 31, 2021 and 2020 , the Company had no off-balance sheet risk. |
Foreign Exchange | Foreign Exchange As a result of certain intercompany transactions in September 2021, the Company has determined that the functional currency for AlloVir International and AlloVir Italia is the U.S. Dollar (“USD”). Prior to this determination, the functional currency of AlloVir International and Allovir Italia was the Euro; however, due to the immateriality of the transactions that occurred at AlloVir International and AlloVir Italia previously, the impact of the determination for the transition from Euro to USD is not material and is not considered a change in accounting principle for reporting purposes. Reporting currency has been and remains the USD. Prior to the change in functional currency for AlloVir International and AlloVir Italia, assets and liabilities were translated into USD at the exchange rate in effect on the balance sheet date. Equity balances, other than retained earnings, were translated at historical exchange rates. Income items and expenses were translated at the average exchange rate in effect during the period. Unrealized translation gains and losses were recorded as a cumulative translation adjustment in the consolidated balance sheets. Transactions in foreign currencies are remeasured into the functional currency of the relevant subsidiaries at the exchange rate in effect at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the functional currency at exchange rates in effect at the balance sheet date or on settlement. Resulting gains and losses are recorded in "other income (loss), net" within the consolidated statements of operations and comprehensive loss. |
Comprehensive Loss | Comprehensive Loss Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. Comprehensive loss includes net loss and certain changes in stockholder’s deficit that are excluded from net loss. The Company had a net change in available-for-sale securities and a foreign currency translation adjustment during the years ended December 31, 2021 and 2020, which met the criteria as other comprehensive income and, therefore, the Company’s comprehensive loss includes unrealized gains (losses) on those available-for-sale securities and foreign currency translation adjustments from foreign subsidiaries prior to the change in functional currency for AlloVir International and AlloVir Italia |
Leases | Leases Effective January 1, 2019 , the Company adopted and accounts for its leases under ASC 842, Leases (“ASC 842”), using the modified retrospective transition approach, as applied to the earliest comparative period presented. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease. Leases with a term greater than one year are recognized on the consolidated balance sheet as a right-of-use (“ROU”) asset and current and non-current lease liabilities, as applicable. The Company has made an accounting policy election, known as the short-term lease recognition exemption, which allows the Company to not recognize ROU assets and lease liabilities that arise from short-term leases (12 months or less) for any class of underlying asset. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew or options to cancel a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew or will not cancel, respectively. The Company monitors its leases on a quarterly basis. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected remaining lease term. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense. Certain adjustments to the ROU asset may be required for items such as lease prepayments or incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. The Company has elected to account for the lease and non-lease components together for all existing classes of underlying assets. |
Subsequent Events | Subsequent Events The Company evaluates events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. The Company did not identify any material subsequent events requiring adjustment to our accompanying consolidated financial statements (recognized subsequent events). Those items requiring disclosure (unrecognized subsequent events) in the consolidated financial statements have been disclosed accordingly. Refer to Note 17 for further details. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”), or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s consolidated financial statements upon adoption. Under the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with certain new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. As noted below, certain new or revised accounting standards were early adopted. |
Recently Adopted Accounting Pronouncements | Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12 – Income Taxes (Topic 740) (“ASU 2019-12”), which removes certain exceptions from the guidance and simplifies the accounting for income taxes in certain areas. The Company adopted ASU 2019-12 on January 1, 2021 . There was no material impact to the Company’s consolidated financial statements as a result of adopting this new standard. |
Recently Issued Accounting Pronouncements Not Yet Adopted | Recently Issued Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326) : Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 significantly changes the impairment model for most financial assets and certain other instruments. ASU 2016-13 will require immediate recognition of estimated credit losses expected to occur over the remaining life of many financial assets, which will generally result in earlier recognition of allowances for credit losses on loans and other financial instruments. ASU 2016-13 is effective for the Company’s fiscal year beginning after December 15, 2022 and subsequent interim periods. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements and related disclosures. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Schedule of Estimated Useful Life | The Company records property and equipment at cost and recognizes depreciation using the straight-line method over the estimated useful lives of the respective assets , as follows: Asset category Estimated useful life Computer equipment 3 years Laboratory equipment 5 years |
Short-Term Investments (Tables)
Short-Term Investments (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Investments, Debt and Equity Securities [Abstract] | |
Summary of Amortized Cost and Estimated Fair Value of Marketable Securities | The following tables summarize the amortized cost and estimated fair value of the Company’s marketable securities, which are considered to be available-for-sale investments and were included in short-term investments on the consolidated balance sheets: December 31, 2021 (in thousands) Amortized Unrealized Unrealized Fair U.S. government treasury securities $ 25,092 $ — $ ( 20 ) $ 25,072 Marketable securities: Commercial paper 11,568 1 — 11,569 Corporate bonds 9,821 — ( 3 ) 9,818 Totals $ 46,481 $ 1 $ ( 23 ) $ 46,459 December 31, 2020 (in thousands) Amortized Unrealized Unrealized Fair U.S. government treasury securities $ 233,687 $ — $ ( 24 ) $ 233,663 Totals $ 233,687 $ — $ ( 24 ) $ 233,663 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Fair Value Disclosures [Abstract] | |
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis | The following tables present information about the Company’s financial assets measured at fair value on a recurring basis: December 31, 2021 (in thousands) Level 1 Level 2 Level 3 Total Cash equivalents: Money market fund $ 141,378 $ — $ — $ 141,378 Marketable securities: Commercial paper — 7,998 — 7,998 Corporate bonds — 753 — 753 Totals $ 141,378 $ 8,751 $ — $ 150,129 Short-term investments: U.S. government treasury securities $ 25,072 $ — $ — $ 25,072 Marketable securities: Commercial paper — 11,569 $ — 11,569 Corporate bonds — 9,818 — 9,818 Totals $ 25,072 $ 21,387 $ — $ 46,459 December 31, 2020 (in thousands) Level 1 Level 2 Level 3 Total Cash equivalents: Money market fund $ 55,505 $ — $ — $ 55,505 U.S. government treasury securities 39,998 — — 39,998 Totals $ 95,503 $ — $ — $ 95,503 Short-term investments: U.S. government treasury securities $ 233,663 $ — $ — $ 233,663 Totals $ 233,663 $ — $ — $ 233,663 |
Leases (Tables)
Leases (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Leases [Abstract] | |
Summary of Maturities Operating Leases Liabilities | Maturities of operating lease liabilities at December 31, 2021 are as follows (in thousands): 2022 $ 7,767 2023 5,273 2024 3,177 2025 3,255 2026 3,334 Thereafter 13,247 Total lease payments 36,053 Less: interest ( 3.40 % - 5.75 %) ( 5,987 ) Total lease liability $ 30,066 Lease liability – current $ 6,591 Lease liability – long-term $ 23,475 |
Property and Equipment, Net (Ta
Property and Equipment, Net (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Property, Plant and Equipment [Abstract] | |
Schedule of Property and Equipment, Net | Property and equipment, net consisted of the following: December 31, (in thousands) 2021 2020 Laboratory equipment $ 1,395 $ 368 Computer equipment 435 — Construction-in-progress — 536 Total property and equipment 1,830 904 Less: accumulated depreciation ( 281 ) ( 92 ) Property and equipment, net $ 1,549 $ 812 |
Accrued Expenses (Tables)
Accrued Expenses (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Payables and Accruals [Abstract] | |
Schedule of Accrued Expenses | Accrued expenses consisted of the following: December 31, (in thousands) 2021 2020 Employee compensation and benefits $ 6,867 $ 3,314 Professional fees 738 696 Research and development 3,573 1,797 Process development and manufacturing costs 7,685 1,550 Other 1,289 173 Total accrued expenses $ 20,152 $ 7,530 |
Stockholder's Equity (Tables)
Stockholder's Equity (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Equity [Abstract] | |
Schedule of Reserved Shares of Common Stock for Issuance | The Company has reserved shares of common stock for issuance as follows: December 31, 2021 2020 Unvested restricted stock 2,866,909 3,410,979 Options to purchase common stock 6,155,055 3,972,909 Stock available for grant under the 2020 Stock Option and Grant Plan 3,812,396 3,895,961 Total 12,834,360 11,279,849 |
Stock-Based Compensation (Table
Stock-Based Compensation (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Summary of Restricted Common Stock Activity | The following table summarizes restricted common stock activity for the year ended December 31, 2021: Shares Weighted Unvested at January 1, 2021 3,410,979 $ 3.55 Granted 1,192,513 33.61 Forfeited ( 127,104 ) 25.91 Vested ( 1,609,479 ) 2.87 Unvested at December 31, 2021 2,866,909 $ 15.45 |
Summary of Stock Option Activity | The following table summarizes stock option activity (in thousands, except share and per share data): Shares Weighted Weighted Aggregate Options outstanding at January 1, 2021 3,972,909 $ 17.84 9.6 $ 81,822 Granted 2,478,888 32.41 — Exercised ( 25,152 ) 9.25 274 Forfeited ( 271,590 ) 25.31 1,047 Options outstanding at December 31, 2021 6,155,055 $ 23.42 8.8 $ 480 Options vested and exercisable at December 31, 2021 1,310,019 $ 17.87 8.6 $ 294 |
Schedule of Estimated Fair Value Weighted-Average Assumptions Using Black-Scholes Option-Pricing Model | The fair value was estimated on the date of grant using the Black-Scholes option-pricing model, with the following weighted-average assumptions: Years Ended December 31, 2021 2020 Expected term (in years) 6.06 6.08 Expected volatility 95 % 95 % Risk-free interest rate 0.87 % 0.36 % Expected dividend yield — — Fair value of common stock $ 32.41 $ 18.08 |
Schedule of Stock-based Compensation Expense | Stock-based compensation expense was as follows: Years Ended December 31, (in thousands) 2021 2020 Research and development $ 20,632 $ 3,571 General and administrative 23,343 5,858 Total stock-based compensation expense $ 43,975 $ 9,429 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
Summary of Income (Loss) Before Provision for Income Taxes | Income (loss) before provision for income taxes consisted of the following: Years Ended December 31, (in thousands) 2021 2020 Federal 49,045 ( 68,356 ) Foreign ( 220,000 ) ( 1,428 ) Loss before provision for income taxes $ ( 170,955 ) $ ( 69,784 ) |
Schedule of Provision for Income Taxes | The provision for income taxes for the years ended December 31, 2021 and 2020 consisted of the following: Years Ended December 31, (in thousands) 2021 2020 Current income tax expense (benefit): Federal $ 987 — State 20 — Foreign — — Total current income tax expense (benefit) 1,007 — Deferred income tax expense (benefit): Federal — — State — — Foreign — — Total deferred income tax expense (benefit) — — Total income tax expense (benefit) $ 1,007 $ — |
Schedule of Income Tax Expense (Benefit) Reconciliation | The Company’s income tax expense (benefit) for the years ended December 31, 2021 and 2020 relating to federal, state and foreign tax jurisdictions differs from the amounts determined by applying the statutory federal income tax rate based on the following: Years Ended December 31, (in thousands) 2021 2020 Benefit at the federal rate $ ( 35,901 ) 21.0 % $ ( 14,655 ) 21.0 % Increase (decrease) resulting from: Foreign tax rate differential 43,786 ( 25.6 )% — — State taxes, net of federal benefit 1,018 ( 0.6 )% ( 1,943 ) 2.8 % Change in valuation allowance 22,268 ( 13.0 )% 17,756 ( 25.4 %) Intellectual property transfer ( 25,538 ) 14.9 % — — Tax credits ( 5,540 ) 3.3 % ( 1,220 ) 1.7 % Officer's compensation 2,648 ( 1.5 )% — — Stock compensation ( 2,464 ) 1.4 % — — Other 730 ( 0.5 )% 62 ( 0.1 )% Total Income Tax Expense (Benefit) $ 1,007 ( 0.6 )% $ — — |
Summary of Components of Deferred Income Taxes | Components of deferred income taxes consist of the following: December 31, (in thousands) 2021 2020 Deferred tax assets: Net operating loss carryforwards $ 5,460 $ 20,866 Tax credit carryforwards 4,683 2,215 Intangible Assets 25,538 — Operating lease liabilities 6,865 2,244 Non-qualified stock compensation 8,028 1,326 Restricted stock compensation 1,778 — Other 1,646 910 Total deferred tax assets 53,998 27,561 Valuation allowance ( 46,823 ) ( 24,555 ) Net deferred tax asset (liability) $ 7,175 $ 3,006 Deferred tax liabilities: Operating lease right-of-use assets ( 6,791 ) ( 2,244 ) Restricted stock compensation — ( 629 ) Depreciation ( 350 ) ( 65 ) Other ( 34 ) ( 68 ) Total deferred tax liabilities ( 7,175 ) ( 3,006 ) Net deferred tax asset (liability) $ — $ — |
Net Loss per Share (Tables)
Net Loss per Share (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Earnings Per Share [Abstract] | |
Computation Of Basic And Diluted Net Loss Per Share Attributable To Common Stockholders | The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company: Years Ended December 31, (in thousands, except share and per share data) 2021 2020 Numerator: Net loss – basic and diluted $ ( 171,962 ) $ ( 69,874 ) Denominator: Weighted-average common shares outstanding – basic and diluted 62,782,126 26,897,390 Net loss per share – basic and diluted $ ( 2.74 ) $ ( 2.59 ) |
Potential Dilutive Securities Excluded From Computation Of Diluted Net Loss Per Share Attributable To Common Stockholders | Based on the amounts outstanding at December 31, 2021 and 2020, the Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders for the years ended December 31, 2021 and 2020, because including them would have had an anti-dilutive effect. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. Years Ended December 31, 2021 2020 Options to purchase common stock 6,155,055 3,972,909 Unvested restricted stock 2,866,909 3,410,979 |
Nature of the Business - Additi
Nature of the Business - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands | Aug. 03, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | Aug. 04, 2020 |
Net proceeds from issuance initial public offering | $ 292,000 | $ 295,449 | ||
Net losses attributable to common stockholders | $ (171,962) | (69,784) | ||
Accumulated deficit | 297,065 | 125,103 | ||
Cash and cash equivalents | 201,661 | 122,661 | ||
Short-term investments | $ 46,459 | $ 233,663 | ||
Convertible Preferred Stock | ||||
Preferred stock, shares outstanding | 0 | |||
Common Stock | ||||
Common stock issued and sold | 18,687,500 | |||
Stock issued upon conversion of preferred stock | 39,859,139 | |||
IPO | ||||
Common stock issued and sold | 18,687,500 | |||
Public offering price per share | $ 17 | |||
Gross proceeds from issuance of common stock | $ 317,700 | |||
Stock issued upon conversion of preferred stock | 39,859,139 | |||
IPO | Common Stock | ||||
Stock issued upon conversion of preferred stock | 39,859,139 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies - Additional Information (Details) | 12 Months Ended | |
Dec. 31, 2021USD ($)SegmentSecurity | Dec. 31, 2020USD ($)Security | |
Summary Of Significant Accounting Policies [Line Items] | ||
Number of operating segment | Segment | 1 | |
Cash and cash equivalents maturity period | 3 months | |
Short-term investments maturity period | 1 year | |
Number of individual securities with impairments | Security | 0 | 0 |
Restricted cash | $ 0 | |
Property, plant and equipment, valuation basis | cost | |
Property, plant and equipment, depreciation methods | recognizes depreciation using the straight-line method over the estimated useful lives of the respective assets | |
Impairment losses on long-lived assets | $ 0 | 0 |
Deferred offering costs | 0 | 0 |
Amortization expense for cloud computing arrangements | $ 100,000 | $ 0 |
Expected dividend yield | 0.00% | 0.00% |
Off-balance sheet risk description | At December 31, 2021 and 2020, the Company had no off-balance sheet risk. | |
ASU 2016-02 | ||
Summary Of Significant Accounting Policies [Line Items] | ||
Change in accounting principle, ASU, adopted | true | |
Change in accounting principle, ASU, adoption date | Jan. 1, 2019 | |
ASU 2019-12 | ||
Summary Of Significant Accounting Policies [Line Items] | ||
Change in accounting principle, ASU, adopted | true | |
Change in accounting principle, ASU, adoption date | Jan. 1, 2021 | |
Change in accounting principle, ASU, immaterial effect | true | |
Internal-use Software | ||
Summary Of Significant Accounting Policies [Line Items] | ||
Expected useful life | 3 years |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Schedule of Estimated Useful Life (Details) | 12 Months Ended |
Dec. 31, 2021 | |
Computer Equipment | |
Summary Of Significant Accounting Policies [Line Items] | |
Estimated useful life | 3 years |
Laboratory Equipment | |
Summary Of Significant Accounting Policies [Line Items] | |
Estimated useful life | 5 years |
Short-Term Investments - Summar
Short-Term Investments - Summary of Amortized Cost and Estimated Fair Value of Marketable Securities (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Schedule Of Available For Sale Securities [Line Items] | ||
Amortized Cost | $ 46,481 | $ 233,687 |
Unrealized Gains | 1 | 0 |
Unrealized Losses | (23) | (24) |
Fair Value | 46,459 | 233,663 |
Commercial paper | ||
Schedule Of Available For Sale Securities [Line Items] | ||
Amortized Cost | 11,568 | |
Fair Value | 11,569 | |
Corporate bonds | ||
Schedule Of Available For Sale Securities [Line Items] | ||
Amortized Cost | 9,821 | |
Unrealized Losses | (3) | |
Fair Value | 9,818 | |
U.S. Government Treasury Securities | ||
Schedule Of Available For Sale Securities [Line Items] | ||
Amortized Cost | 25,092 | 233,687 |
Unrealized Gains | 0 | |
Unrealized Losses | (20) | (24) |
Fair Value | $ 25,072 | $ 233,663 |
Fair Value Measurements - Summa
Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value On Recurring Basis (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Cash equivalents: | ||
Cash equivalents | $ 150,129 | $ 95,503 |
Short-term investments: | ||
Short-term investments | 46,459 | 233,663 |
Commercial paper | ||
Cash equivalents: | ||
Cash equivalents | 7,998 | |
Short-term investments: | ||
Short-term investments | 11,569 | |
Corporate bonds | ||
Cash equivalents: | ||
Cash equivalents | 753 | |
Short-term investments: | ||
Short-term investments | 9,818 | |
Money Market Fund | ||
Cash equivalents: | ||
Cash equivalents | 141,378 | 55,505 |
U.S. Government Treasury Securities | ||
Cash equivalents: | ||
Cash equivalents | 39,998 | |
U.S. Government Treasury Securities | ||
Short-term investments: | ||
Short-term investments | 25,072 | 233,663 |
Level 1 | ||
Cash equivalents: | ||
Cash equivalents | 141,378 | 95,503 |
Short-term investments: | ||
Short-term investments | 25,072 | 233,663 |
Level 1 | Money Market Fund | ||
Cash equivalents: | ||
Cash equivalents | 141,378 | 55,505 |
Level 1 | U.S. Government Treasury Securities | ||
Cash equivalents: | ||
Cash equivalents | 39,998 | |
Level 1 | U.S. Government Treasury Securities | ||
Short-term investments: | ||
Short-term investments | 25,072 | $ 233,663 |
Level 2 | ||
Cash equivalents: | ||
Cash equivalents | 8,751 | |
Short-term investments: | ||
Short-term investments | 21,387 | |
Level 2 | Commercial paper | ||
Cash equivalents: | ||
Cash equivalents | 7,998 | |
Short-term investments: | ||
Short-term investments | 11,569 | |
Level 2 | Corporate bonds | ||
Cash equivalents: | ||
Cash equivalents | 753 | |
Short-term investments: | ||
Short-term investments | $ 9,818 |
Leases - Additional Information
Leases - Additional Information (Details) - USD ($) | Jan. 31, 2022 | Sep. 30, 2021 | Apr. 30, 2021 | Feb. 28, 2021 | Sep. 30, 2019 | Jul. 31, 2019 | Dec. 31, 2021 | Dec. 31, 2020 | Mar. 31, 2019 |
Leases [Line Items] | |||||||||
Lease expiration month and year | 2022-09 | ||||||||
Short-term lease expenses | $ 400,000 | $ 400,000 | |||||||
Non-lease costs | 37,500 | 58,200 | |||||||
ROU asset | 29,743,000 | 8,692,000 | |||||||
Lease liability | 30,066,000 | ||||||||
Operating lease costs | 6,200,000 | 4,000,000 | |||||||
Cash paid for operating lease | 5,200,000 | 3,600,000 | |||||||
Variable non-lease costs | $ 14,500,000 | 4,500,000 | |||||||
Operating lease, weighted average remaining lease term | 7 years 2 months 1 day | ||||||||
Operating lease, weighted average discount rate, percent | 4.96% | ||||||||
Subsequent Event | |||||||||
Leases [Line Items] | |||||||||
Lease termination date | Jan. 31, 2022 | ||||||||
DMS Agreement | |||||||||
Leases [Line Items] | |||||||||
Lease expiration month and year | 2021-07 | ||||||||
Lease effective date | 2021-04 | 2019-07 | |||||||
Lease termination description | On July 30, 2021, the Company provided a notification to reduce capacity to the third-party supplier which terminates this lease agreement in the first quarter of 2022. | ||||||||
Lease expense recognized | $ 500,000 | $ 0 | |||||||
Term of agreement | 2 years | ||||||||
Operating lease, existence of option to extend | true | ||||||||
Lease, option to extend | The term may be extended by agreement of the parties for additional two-year periods upon written notice to the supplier at least 30 days prior to expiration of the then-current term. | ||||||||
Operating lease, existence of option to terminate | true | ||||||||
Lease, option to terminate | The DMS Agreement (or any individual SOW) may be terminated earlier by AlloVir at any time by providing 190 days’ notice. | ||||||||
Lease renewal term | 2 years | ||||||||
Estimated lease term | 3 years 9 months | 4 years 3 months | |||||||
Estimated lease expiring month and year | 2023-07 | 2023-07 | |||||||
ROU asset | $ 6,300,000 | $ 6,900,000 | |||||||
Lease liability | $ 6,300,000 | $ 6,900,000 | |||||||
2020 DMS Agreement | |||||||||
Leases [Line Items] | |||||||||
Term of agreement | 1 year | ||||||||
Lease renewal term | 1 year | ||||||||
Estimated lease term | 2 years | ||||||||
Estimated lease expiring month and year | 2023-01 | ||||||||
ROU asset | $ 3,100,000 | ||||||||
Lease liability | 2,500,000 | ||||||||
Utilization fee | $ 3,200,000 | ||||||||
Lessee operating lease, lease term including renewal option | 2 years | ||||||||
Prepaid utilization fee | $ 600,000 | ||||||||
Waltham Leases | |||||||||
Leases [Line Items] | |||||||||
Expiration date | Jul. 30, 2030 | ||||||||
Operating lease, existence of option to extend | true | ||||||||
Lease, option to extend | The Company has the option to renew the leased space for an additional one time period of five years with written notice from the Company. As of December 31, 2021, the Company has no reasonable certainty that this option to extend will be exercised. | ||||||||
Lease commencement month and year | 2021-09 | ||||||||
Additional one time lease period | 5 years | ||||||||
Tenant improvement allowance to be reimbursed | $ 3,100,000 | ||||||||
Tenant improvement allowance, reimbursement period | 2 years | ||||||||
Tenant improvement allowance | $ 0 | ||||||||
New Lease Agreement with BP Bay Colony LLC | |||||||||
Leases [Line Items] | |||||||||
ROU asset | $ 6,000,000 | ||||||||
Lease liability | 6,000,000 | ||||||||
Sublease with AMAG Pharmaceuticals | |||||||||
Leases [Line Items] | |||||||||
ROU asset | 17,300,000 | ||||||||
Lease liability | $ 17,300,000 |
Leases - Summary of Operating L
Leases - Summary of Operating Lease Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Leases [Abstract] | ||
2022 | $ 7,767 | |
2023 | 5,273 | |
2024 | 3,177 | |
2025 | 3,255 | |
2026 | 3,334 | |
Thereafter | 13,247 | |
Total lease payments | 36,053 | |
Less: interest (3.40% - 5.75%) | (5,987) | |
Total lease liability | 30,066 | |
Lease liability – current | 6,591 | $ 3,229 |
Lease liability – long-term | $ 23,475 | $ 5,463 |
Leases - Summary of Operating_2
Leases - Summary of Operating Lease Liabilities (Details) (Parenthetical) | Dec. 31, 2021 |
Lessor Lease Description [Line Items] | |
Operating lease interest percentage | 4.96% |
Minimum | |
Lessor Lease Description [Line Items] | |
Operating lease interest percentage | 3.40% |
Maximum | |
Lessor Lease Description [Line Items] | |
Operating lease interest percentage | 5.75% |
Property and Equipment, Net - S
Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Property Plant And Equipment [Line Items] | ||
Total property and equipment | $ 1,830 | $ 904 |
Less: accumulated depreciation | (281) | (92) |
Property and equipment, net | 1,549 | 812 |
Laboratory equipment | ||
Property Plant And Equipment [Line Items] | ||
Total property and equipment | 1,395 | 368 |
Computer equipment | ||
Property Plant And Equipment [Line Items] | ||
Total property and equipment | $ 435 | |
Construction-in-Progress | ||
Property Plant And Equipment [Line Items] | ||
Total property and equipment | $ 536 |
Property and Equipment, Net - A
Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Property, Plant and Equipment [Abstract] | ||
Depreciation expenses | $ 0.2 | $ 0.1 |
Accrued Expenses - Schedule of
Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Payables and Accruals [Abstract] | ||
Employee compensation and benefits | $ 6,867 | $ 3,314 |
Professional fees | 738 | 696 |
Research and development | 3,573 | 1,797 |
Process development and manufacturing costs | 7,685 | 1,550 |
Other | 1,289 | 173 |
Total accrued expenses | $ 20,152 | $ 7,530 |
Sponsored Research, Collabora_2
Sponsored Research, Collaboration and License Agreements - Additional Information (Details) | 1 Months Ended | 12 Months Ended | |||||
Nov. 30, 2020USD ($) | Dec. 31, 2019USD ($) | Jun. 30, 2019USD ($)Installment | Aug. 31, 2017USD ($) | Jun. 30, 2017USD ($) | Dec. 31, 2021USD ($)Milestone | Dec. 31, 2020USD ($) | |
Sponsored Research, Collaboration and License Agreements [Line Items] | |||||||
Research and development expense | $ 120,735,000 | $ 49,663,000 | |||||
Number of milestone events | Milestone | 3 | ||||||
CPRIT | License agreement terms | |||||||
Sponsored Research, Collaboration and License Agreements [Line Items] | |||||||
Maximum paid percentage of grant award proceeds until which revenue share is payable | 400.00% | ||||||
Royalty payments | $ 0 | 0 | |||||
CPRIT | Grant | |||||||
Sponsored Research, Collaboration and License Agreements [Line Items] | |||||||
Revenue from grant | $ 9,000,000 | ||||||
Period of grant | 3 years | ||||||
Percentage of obligation of grant funds used | 50.00% | ||||||
Cost incurred to obtain or fulfill the contract | $ 0 | ||||||
Grant funds received returned amount | $ 2,600,000 | ||||||
Interest relating to grant funds returned | 100,000 | ||||||
Deferred revenue balance | $ 0 | ||||||
A&R License Agreement | BCM | |||||||
Sponsored Research, Collaboration and License Agreements [Line Items] | |||||||
Non-refundable license fee payments | $ 250,000 | ||||||
Milestone payments | $ 40,000,000 | ||||||
Minimum percentage of eligible to receive tiered royalties | 1.00% | ||||||
Second License Agreement | BCM | |||||||
Sponsored Research, Collaboration and License Agreements [Line Items] | |||||||
Non-refundable license fee payments | $ 125,000 | ||||||
Milestone payments | $ 30,000,000 | ||||||
Minimum percentage of eligible to receive tiered royalties | 1.00% | ||||||
Non-refundable license fee payments, first year through fourth anniversary of effective date | $ 20,000 | ||||||
Non-refundable license fee payments fifth anniversary of effective date and continuing thereafter | 40,000 | ||||||
SRA-2 | BCM | |||||||
Sponsored Research, Collaboration and License Agreements [Line Items] | |||||||
Agreement for research activities, term | 1 year | ||||||
Agreement for research activities, additional term with written consent | 1 year | ||||||
Research activities performing fees | $ 1,000,000 | ||||||
Number of installment for research activities payments | Installment | 4 | ||||||
Research Agreement | BCM | |||||||
Sponsored Research, Collaboration and License Agreements [Line Items] | |||||||
Agreement for research activities, term | 3 years | ||||||
Research activities performing fees | $ 2,000,000 | ||||||
Total research activities performing fees, over the term | $ 6,000,000 | ||||||
Collective Agreements | BCM | |||||||
Sponsored Research, Collaboration and License Agreements [Line Items] | |||||||
Research and development expense | 3,300,000 | $ 1,100,000 | |||||
Collective Agreements | BCM | Accured member | |||||||
Sponsored Research, Collaboration and License Agreements [Line Items] | |||||||
Accrued milestone expenses | $ 200,000 |
Funding Arrangements - Addition
Funding Arrangements - Additional Information (Details) - Grant - USD ($) $ in Millions | 1 Months Ended | 12 Months Ended | |
Jun. 30, 2017 | Dec. 31, 2021 | Dec. 31, 2020 | |
Research And Development Arrangement Contract To Perform For Others [Line Items] | |||
Research grant, description and terms | In June 2017, the Company was awarded a Small Business Innovation Research (“SBIR”) grant by the National Institute of Health (“NIH”) in the amount of $3.0 million. This grant was effective from September 15, 2017 to June 30, 2020 and in April 2020, the Company received an extension through June 30, 2021. | ||
Research revenue grant awarded | $ 3 | ||
Grant revenue received | $ 0 | $ 0.9 | |
Research related income recognized | $ 0 | $ 0.6 |
Stockholders Equity - Additiona
Stockholders Equity - Additional Information (Details) | Aug. 03, 2020USD ($)$ / sharesshares | Dec. 31, 2021USD ($)Vote$ / sharesshares | Dec. 31, 2020$ / sharesshares |
Class Of Stock [Line Items] | |||
Preferred stock, par or stated value per share | $ / shares | $ 0.0001 | $ 0.0001 | |
Preferred stock, shares authorized | 10,000,000 | 10,000,000 | |
Preferred stock, shares issued | 0 | 0 | |
Preferred stock, shares outstanding | 0 | 0 | |
Common stock, shares authorized | 150,000,000 | 150,000,000 | |
Common stock, par value | $ / shares | $ 0.0001 | $ 0.0001 | |
Number of votes per share | Vote | 1 | ||
Common stock, voting rights | The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders (and written actions in lieu of meetings), and there are not any cumulative voting rights. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of shares of capital stock of the Company; however, the issuance of common stock may be subject to the vote of the holders of one or more series of preferred stock that may be required by terms of the Third Amended and Restated Certificate of Incorporation. | ||
Cash dividends declared or paid | $ | $ 0 | ||
IPO | |||
Class Of Stock [Line Items] | |||
Preferred stock, par or stated value per share | $ / shares | $ 0.0001 | ||
Preferred stock, shares authorized | 10,000,000 | ||
Common stock issued and sold | 18,687,500 | ||
Public offering price per share | $ / shares | $ 17 | ||
Proceeds from issuance of common stock | $ | $ 292,000,000 | ||
Stock issued upon conversion of preferred stock | 39,859,139 | ||
Over-Allotment Option | |||
Class Of Stock [Line Items] | |||
Common stock issued and sold | 2,437,500 |
Stockholders Equity - Schedule
Stockholders Equity - Schedule of Reserved Shares of Common Stock for Issuance (Details) - shares | Dec. 31, 2021 | Dec. 31, 2020 |
Class Of Stock [Line Items] | ||
Reserved shares of common stock for issuance | 12,834,360 | 11,279,849 |
2018 Equity Incentive Plan | ||
Class Of Stock [Line Items] | ||
Reserved shares of common stock for issuance | 0 | |
2020 Stock Option and Grant Plan | ||
Class Of Stock [Line Items] | ||
Reserved shares of common stock for issuance | 3,812,396 | |
Unvested Restricted Stock | ||
Class Of Stock [Line Items] | ||
Reserved shares of common stock for issuance | 2,866,909 | 3,410,979 |
Option To Purchase Common Stock | ||
Class Of Stock [Line Items] | ||
Reserved shares of common stock for issuance | 6,155,055 | 3,972,909 |
Stock Available for Grant | 2020 Stock Option and Grant Plan | ||
Class Of Stock [Line Items] | ||
Reserved shares of common stock for issuance | 3,812,396 | 3,895,961 |
Stock-Based Compensation - Addi
Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions | Jan. 01, 2022 | Jul. 02, 2020 | Jul. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
Reserved shares of common stock for issuance | 12,834,360 | 11,279,849 | |||
Weighted average grant-date fair value of stock options granted | $ 24.76 | $ 13.77 | |||
Common stock, par value | $ 0.0001 | 0.0001 | |||
Restricted Common Stock | |||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
Awards forfeited or cancelled | 127,104 | ||||
Number of shares granted | 1,192,513 | ||||
Weighted average grant date fair value of restricted stock granted | $ 33.61 | 21.07 | |||
Weighted average grant date fair value of restricted stock vested | $ 2.87 | $ 1.84 | |||
Unrecognized stock-based compensation cost | $ 34.1 | ||||
Weighted average period of cost expected to be recognized | 3 years 3 days | ||||
Stock Options | |||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
Weighted average period of cost expected to be recognized | 2 years 10 months 17 days | ||||
Unrecognized stock-based compensation expenses | $ 73.5 | ||||
2018 Equity Incentive Plan | |||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
Awards vesting period | 4 years | ||||
Awards contractual term | 10 years | ||||
Common stock shares granted | 6,715,415 | ||||
Number of shares of common stock issuable upon exercise of outstanding options | 64,042 | ||||
Awards forfeited or cancelled | 31,600 | ||||
Reserved shares of common stock for issuance | 0 | ||||
2020 Stock Option and Grant Plan | |||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
Awards vesting period | 4 years | ||||
Awards contractual term | 10 years | ||||
Reserved shares of common stock for issuance | 3,812,396 | ||||
Common stock authorized for issuance | 8,008,734 | ||||
Cumulative increase in number shares reserved for issuance, percentage | 5.00% | ||||
Common stock issuable upon exercise of outstanding options | 6,091,013 | ||||
2020 Stock Option and Grant Plan | Restricted Common Stock | |||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
Number of shares granted | 1,443,520 | ||||
2020 Stock Option and Grant Plan | Subsequent Event | |||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
Shares added to number of available shares under plan | 3,258,517 | ||||
2020 ESPP | |||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
Reserved shares of common stock for issuance | 611,354 | ||||
Cumulative increase in number shares reserved for issuance, percentage | 1.00% | ||||
Common stock, par value | $ 0.0001 | ||||
Annual increase in number of shares reserved for issuance | 1,222,707 |
Stock-Based Compensation - Summ
Stock-Based Compensation - Summary of Restricted Common Stock Activity (Details) - Restricted Common Stock - $ / shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Number of Shares | ||
Number of Shares, Unvested at January 1, 2021 | 3,410,979 | |
Number of Shares, Granted | 1,192,513 | |
Number of Shares, Forfeited | (127,104) | |
Number of Shares, Vested | (1,609,479) | |
Number of Shares, Unvested at December 31, 2021 | 2,866,909 | 3,410,979 |
Weighted Average Grant Date Fair Value | ||
Weighted Average Grant Date Fair Value, Unvested at January 1, 2021 | $ 3.55 | |
Weighted Average Grant Date Fair Value, Granted | 33.61 | $ 21.07 |
Weighted Average Grant Date Fair Value, Forfeited | 25.91 | |
Weighted Average Grant Date Fair Value, Vested | 2.87 | 1.84 |
Weighted Average Grant Date Fair Value, Unvested at December 31, 2021 | $ 15.45 | $ 3.55 |
Stock-Based Compensation - Su_2
Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based Payment Arrangement [Abstract] | ||
Number of Options Outstanding, Beginning Balance | 3,972,909 | |
Number of Options, Granted | 2,478,888 | |
Number of Options, Exercised | (25,152) | |
Number of Options, Forfeited | (271,590) | |
Number of Options Outstanding, Ending Balance | 6,155,055 | 3,972,909 |
Options vested and exercisable at December 31, 2021 | 1,310,019 | |
Weighted Average Exercise Price, Options outstanding at January 1, 2021 | $ 17.84 | |
Weighted Average Exercise Price, Granted | 32.41 | |
Weighted Average Exercise Price, Exercised | 9.25 | |
Weighted Average Exercise Price, Forfeited | 25.31 | |
Weighted Average Exercise Price, Options outstanding at December 31, 2021 | 23.42 | $ 17.84 |
Weighted Average Exercise Price, Options vested and exercisable at December 31, 2021 | $ 17.87 | |
Weighted Average Contractual Life, Options outstanding | 8 years 9 months 18 days | 9 years 7 months 6 days |
Weighted Average Contractual Life, Options vested and exercisable at December 31, 2021 | 8 years 7 months 6 days | |
Aggregate Intrinsic Value, Options outstanding at January 1, 2021 | $ 81,822 | |
Aggregate Intrinsic Value, Exercised | 274 | |
Aggregate Intrinsic Value, Forfeited | 1,047 | |
Aggregate Intrinsic Value, Options outstanding at December 31, 2021 | 480 | $ 81,822 |
Aggregate Intrinsic Value, Options vested and exercisable at December 31, 2021 | $ 294 |
Stock-Based Compensation - Sche
Stock-Based Compensation - Schedule of Estimated Fair Value Weighted-Average Assumptions Using Black-Scholes Option-Pricing Model (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based Payment Arrangement [Abstract] | ||
Expected term (in years) | 6 years 21 days | 6 years 29 days |
Expected volatility | 95.00% | 95.00% |
Risk-free interest rate | 0.87% | 0.36% |
Expected dividend yield | 0.00% | 0.00% |
Fair value of common stock | $ 32.41 | $ 18.08 |
Stock-Based Compensation - Sc_2
Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||
Stock-based compensation expense | $ 43,975 | $ 9,429 |
Research and Development | ||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||
Stock-based compensation expense | 20,632 | 3,571 |
General and Administrative | ||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||
Stock-based compensation expense | $ 23,343 | $ 5,858 |
Income Taxes - Summary of Incom
Income Taxes - Summary of Income (Loss) Before Provision for Income Taxes (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | ||
Federal | $ 49,045 | $ (68,356) |
Foreign | (220,000) | (1,428) |
Loss before income taxes | $ (170,955) | $ (69,784) |
Income Taxes - Schedule of Prov
Income Taxes - Schedule of Provision for Income Taxes (Details) $ in Thousands | 12 Months Ended |
Dec. 31, 2021USD ($) | |
Current income tax expense (benefit): | |
Federal | $ 987 |
State | 20 |
Total current income tax expense (benefit) | 1,007 |
Deferred income tax expense (benefit): | |
Total income tax expense (benefit) | $ 1,007 |
Income Taxes - Schedule of Inco
Income Taxes - Schedule of Income Tax Expense (Benefit) Reconciliation (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | ||
Benefit at the federal rate | $ (35,901) | $ (14,655) |
Foreign tax rate differential | 43,786 | |
State taxes, net of federal benefit | 1,018 | (1,943) |
Change in valuation allowance | 22,268 | 17,756 |
Intellectual property transfer | (25,538) | |
Tax credits | (5,540) | (1,220) |
Officer's compensation | 2,648 | |
Stock compensation | (2,464) | |
Other | 730 | $ 62 |
Total income tax expense (benefit) | $ 1,007 | |
Benefit at the federal rate | 21.00% | 21.00% |
Foreign tax rate differential | (25.60%) | |
State taxes, net of federal benefit | (0.60%) | 2.80% |
Change in valuation allowance | (13.00%) | (25.40%) |
Intellectual property transfer | 14.90% | |
Tax credits | 3.30% | 1.70% |
Officer's compensation | (1.50%) | |
Stock compensation | 1.40% | |
Other | (0.50%) | (0.10%) |
Total Income Tax Expense (Benefit) | (0.60%) |
Income Taxes - Summary of Compo
Income Taxes - Summary of Components of Deferred Income Taxes (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Deferred tax assets: | ||
Net operating loss carryforwards | $ 5,460 | $ 20,866 |
Tax credit carryforwards | 4,683 | 2,215 |
Intangible Assets | 25,538 | |
Operating lease liabilities | 6,865 | 2,244 |
Non-qualified stock compensation | 8,028 | 1,326 |
Restricted stock compensation | 1,778 | |
Other | 1,646 | 910 |
Total deferred tax assets | 53,998 | 27,561 |
Valuation allowance | (46,823) | (24,555) |
Net deferred tax asset (liability) | 7,175 | 3,006 |
Deferred tax liabilities: | ||
Operating lease right-of-use assets | (6,791) | (2,244) |
Restricted stock compensation | (629) | |
Depreciation | (350) | (65) |
Other | (34) | (68) |
Total deferred tax liabilities | $ (7,175) | $ (3,006) |
Income Taxes - Additional Infor
Income Taxes - Additional Information (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Income Taxes [Line Items] | ||
U.S. current income tax expense | $ 1,007,000 | |
Increase in deferred tax assets valuation allowance | $ 22,268,000 | $ 17,756,000 |
Operating loss carryforwards carryback period | 5 years | |
Percentage of TCJA limitations on net operating loss carryforwards to taxable income | 80.00% | |
Uncertain tax positions | $ 0 | 0 |
Unrecognized tax benefits, interest and penalties accrued | $ 0 | 0 |
Earliest Tax Year | ||
Income Taxes [Line Items] | ||
Open tax year | 2018 | |
Latest Tax Year | ||
Income Taxes [Line Items] | ||
Open tax year | 2021 | |
Federal | ||
Income Taxes [Line Items] | ||
Operating loss carryforwards | $ 13,300,000 | 88,600,000 |
Federal | Research and Development | ||
Income Taxes [Line Items] | ||
Tax credit carryforwards | $ 2,800,000 | 1,800,000 |
Tax credit carryforwards expiration year | 2040 | |
Federal | Orphan Drug Credit (ODC) | ||
Income Taxes [Line Items] | ||
Tax credit carryforwards | $ 1,300,000 | |
Tax credit carryforwards expiration year | 2041 | |
State | ||
Income Taxes [Line Items] | ||
Operating loss carryforwards | $ 8,500,000 | 31,700,000 |
Operating loss carryforwards expiration year | 2035 | |
State | Research and Development | ||
Income Taxes [Line Items] | ||
Tax credit carryforwards | $ 800,000 | 500,000 |
Tax credit carryforwards expiration year | 2035 | |
Foreign | ||
Income Taxes [Line Items] | ||
Operating loss carryforwards | $ 16,800,000 | $ 1,300,000 |
Net Loss per Share - Computatio
Net Loss per Share - Computation Of Basic And Diluted Net Loss Per Share Attributable To Common Stockholders (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Numerator: | ||
Net loss – basic and diluted | $ (171,962) | $ (69,874) |
Denominator: | ||
Weighted-average common shares outstanding – basic and diluted | 62,782,126 | 26,897,390 |
Net loss per share – basic and diluted | $ (2.74) | $ (2.59) |
Net Loss per Share - Potential
Net Loss per Share - Potential Dilutive Securities Excluded From Computation Of Diluted Net Loss Per Share Attributable To Common Stockholders (Details) - shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Options To Purchase Common Stock | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share | 6,155,055 | 3,972,909 |
Unvested Restricted Stock | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share | 2,866,909 | 3,410,979 |
Commitments and Contingencies-
Commitments and Contingencies- Additional Information (Details) $ in Millions | 12 Months Ended |
Dec. 31, 2021USD ($)Batch | |
Commitments and Contingencies Disclosure [Abstract] | |
Lease expiration month and year | 2022-09 |
Sub-lease expiration date | Jan. 31, 2022 |
Minimum number of batch of product required to purchase per month under DMS agreement | Batch | 1 |
Purchase commitment amount per month in DMS agreement | $ | $ 0.3 |
DMS agreement, expiration month and year | 2023-07 |
Related Party Transactions - Ad
Related Party Transactions - Additional Information (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Related Party Transaction [Line Items] | ||
Amount due to related party | $ 1,742 | $ 572 |
Consulting fees to members of management | 500 | 600 |
ElevateBio and Affiliates | ||
Related Party Transaction [Line Items] | ||
Expenses related to services with related party | 5,900 | 7,300 |
Prepaid expenses related to services with related party | 900 | |
Amount due to related party | $ 1,700 | $ 600 |
Employee Benefit Plans - Additi
Employee Benefit Plans - Additional Information (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Retirement Benefits [Abstract] | ||
Matching contributions by employer | $ 0.5 | $ 0.1 |